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ABSTRACT
In this thesis, I, alongside my varied and talented collaborators, aim to integrate two
seemingly disparate subfields of biology: pharmacogenomics and regulatory genomics. The
former concentrates on how inherited factors such as SNPs and genes inform the response
to medical interventions designed to ameliorate disease states, processes, and phenotypes;
ontologically, it resides at the intersection of genomics and pharmacology. Regulatory ge-
nomics, however, directs its attention fully to the biological mechanisms by which genes
express themselves, without regard to application or context. As such, it is viewed within
the intersection of genomics and systems biology. A systems perspective is relevant because
last 20 years of regulatory genomics research have concluded that (a) genes do not necessar-
ily express binarily as a (b) function of logical operations on the presence/absence of a (c)
finite set of protein regulators binding to the (d) genes immediate upstream DNA sequence,
but rather, that the span of regulators ranges from protein DNA binding factors to other
such nuclear factors (including the DNA itself) up and through various signaling molecule
networks to the various components of the cell, terminating at the interface of the cell and ex-
tracellular environment the membrane. DNA accessibility and conformation, cellular type,
micro-RNAs are all real factors that influence gene expression. This thesis, however, assumes
the more nave assumptions of gene regulation namely that the DNA binding proteins, called
Transcription Factors (TFs), influence the kinetics of the transcriptional process by binding
in certain configurations proximal to the genes transcription start site. In combining both
pharmacogenomics and regulatory genomics, it was necessary to make simplifications and
assumptions to the biology on both sides to make the problem tractable; however, as a result,
we were able to construct statistical and probabilistic models that capture novel biological
associations that would otherwise remain unknown. Namely, associations between nuclear
regulators of genes and drug response. In doing so, we provide a novel link in connecting
these two disparate views of biology into a more cohesive and singular picture.
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CHAPTER 1: INTRODUCTION
The field of pharmacogenetics aims to understand the relationship between inter-individual
variation at the genetic level and variation in cellular or physiological response to drug ad-
ministration. Rapidly emerging genomic technologies have expanded the scope of analysis
to genome-wide levels, simultaneously providing a variety of high quality data to enable the
analysis, including genotype1 , gene2 expression3 and proteomic data4 , as well as functional
annotations from the Encyclopedia of Genomic Elements (ENCODE) [1]. Consequently, the
burden has fallen to computational analysts to integrate and explain the current deluge of
biological data, in a manner consistent with both the underlying biological principles and
mechanisms, while also delivering novel insights into the molecular mechanisms underlying
cellular response to drug treatment. This thesis effort to develop statistical and probabilistic
models to elucidate the relationship between regulatory factors and cellular perturbagens.
It is divided into two such chapters: Chapter 2 corresponding to a simple statistical model
that integrates much of our intuition regarding the relationship between primitive biologi-
cal entities and Chapter 3 corresponding to a re-imagining of the model in Chapter 2 in a
probabilistic sense so as to increase model extensibility, interpretability, and interrogability.
To clarify, in shifting from a statistical enrichment test to a probabilistic graphical model
(PGM) that extends the statistical model in a meaningful way, allowing for greater inter-
pretability and integration of heterogeneous data types. We introduce each of these studies
in the following sub-sections.
1.1 GENE EXPRESSION IN THE MIDDLE (GENMI)
This study integrates gene expression, genotype and drug response data in lymphoblas-
toid cell lines with transcription factor (TF)-binding sites from ENCODE (Encyclopedia of
Genomic Elements) in a novel methodology that elucidates regulatory contexts associated
with cytotoxicity. The method, GENMi (Gene Expression iN the Middle), postulates that
1The specific sequence of DNA units (nucleotides or base pairs) which constitute the genome of an
organism. A specific nucleotide can assume one of four types: Adenine, Cytosine, Guanine, and Thymine
abbreviated A,C,G,T. The scale at which genotype refers can vary dramatically in context: from the entire
genome, to DNA segments, to single base pairs.
2A type of DNA segment whose composition encodes recipes to make one or more types of proteins.
3The product or process of transcription, whereby a genes DNA is transcribed into a molecule, mRNA,
that can move freely toward cellular components necessary for protein production.
4Measurements on the quantity and concentration of proteins in a sample. The proteome refers to all
such proteins in a genome while transcriptome refers to all such genes. The gene analog to proteomics is
transcriptomics: the measurements on the quantity and concentration of mRNA transcribed from genes.
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single-nucleotide polymorphisms within TF-binding sites putatively modulate its regulatory
activity, and the resulting variation in gene expression leads to variation in drug response.
Analysis of 161 TFs and 24 treatments revealed 334 significantly associated TFtreatment
pairs. Investigation of 20 selected pairs yielded literature support for 13 of these associations,
often from studies where perturbation of the TF expression changes drug response. Exper-
imental validation of significant GENMi associations in taxanes and anthracyclines across
two triple-negative breast cancer cell lines corroborates our findings. The method is shown
to be more sensitive than an alternative, genome-wide association study-based approach that
does not use gene expression. These results demonstrate the utility of GENMi in identifying
TFs that influence drug response and provide a number of candidates for further testing.
Advances in the burgeoning field of pharmacogenomics [2] have the potential to revolutionize
health care by guiding personalized health care for patients via genome sequencing [3, 4].
1.1.1 BACKGROUND
The de facto method for generating biological hypotheses of clinical relevance involves the
extraction of pharamacogenomic data from human cell lines that are generalizable and easily
manipulated; lymphoblastoid cell lines (LCLs) represent a canonical source with such clear
clinical utility [4, 5, 6]. A number of studies have analyzed such data sets to relate genotypic
variation to drug response [7], revealing important single-nucleotide polymorphisms (SNPs)
as well as SNP-carrying genes that are candidates for functional testing. Parallel to the
identification of SNPs associated with drug response, there is also considerable interest in
characterizing the mechanistic basis of such relationships, that is, pathways and regulatory
networks involved in drug response and its variability [8, 9].
Identifying systems-level components of the response, such as signaling pathways and tran-
scriptional cascades, can enable discovery of novel drug targets and lead to the realization
of precision medicine [10]. Here, we embark upon one such line of enquiryto identify tran-
scription factors (TFs) whose regulatory activities are associated with cellular response to
cytotoxic treatments (Fig 1.1A), with the expectation that in the future the response may
be manipulated by intervening with the function of TF.
The most widely used statistical method for harnessing pharamacogenomic data to iden-
tify biomarkers relevant to drug-induced cellular response is genome-wide association study
(GWAS), where SNPs are analyzed for their correlation with drug response across indi-
viduals. The multigenic origins of phenotypic variability, correlations between proximally
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Figure 1.1: (a) Diagram of how transcription factors (TFs) mediate response to a drug. A
drug (diamond) enters the cell and affects multiple cellular processes. One such process
involves transport or signal transduction to the nucleus where it alters the transcriptional
activity of a TF. Expression of target genes is subsequently altered, potentially resulting in
apoptosis. (b) Outline of triangulation procedure proposed in the literature. Each edge of
the triangle corresponds to a correlation between two of the three axes of information: drug
response, genetic variants and gene expression. Integrative analysis involves intersecting ex-
pression quantitative trait locus (eQTL) genes and genome-wide association study (GWAS)
genes or eQTL single-nucleotide polymorphisms (SNPs) and GWAS SNPs
located SNPs and the need for multiple hypothesis correction over millions of candidate
markers reduce the ability of GWAS to discover casual SNPs. A number of studies have
sought to improve upon the basic GWAS approach, for example, by testing subsets of SNPs
as opposed to single marker analysis, or combining GWAS associations with prior knowl-
edge of gene networks and pathways [11, 12, 13]. We draw inspiration from this emerging
paradigm and attempt to associate drug response variation with multiple SNPs that share
a common functional context, viz., that of being located within binding sites of the same TF.
Functional genotypic variants are expected to exert their influence on phenotypic differ-
ences at least partly through variation in expression levels of nearby genes [14, 15, 16]. A
previous study [17] argued that if gene expression data are available in addition to genotype
and phenotype data on the same cohort, then a statistical approach called mediator analysis
can be employed to discover functional SNPs with greater sensitivity. Gene expression and
proteomic data have often been used to predict phenotypes, including drug-induced cellular
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response [16, 18, 19, 20, 21]. Efforts have been made to develop methodologies that inte-
grate both gene expression and genotype information to predict phenotype. One method of
achieving this is the following: first conduct a GWAS associating SNPs with the phenotype,
and then correlate significant GWAS SNPs with expression of their proximal genes, thereby
identifying expression quantitative trait locus (eQTL) SNPs, and finally correlate expression
of these eQTL genes with phenotype. This triangulation procedure for integrating genotype,
gene expression and phenotype (Fig 1.1B) data has been used to identify either candidate
SNPs or candidate genes for experimentation. It has also been used in pharmacogenomics
to identify biomarkers and genes related to cisplatin-, etoposide- and radiation-induced cy-
totoxicity [22, 23, 24]. These previous studies motivate us to integrate gene expression data
in our search for molecular determinants of drug response variability.
Integration of genotype and expression data in association studies draws our attention
to cis-regulatory SNPs that represent a large proportion of individual variability and have
been linked to important phenotypes, including diseases [25]. A prime difficulty in char-
acterizing regulatory variants is the poor annotation of the noncoding genome, making it
difficult to tell neutral from potentially functional cis-variants. Recent community efforts
to systematically annotate the regulatory genome, such as the ENCODE project, may al-
leviate this problem to an extent. However, few existing approaches incorporate ENCODE
data, in particular, transcription factor-binding site (TFBS) data, into statistical analysis
of individual variation at the genotypic and phenotypic levels. The ENCODE consortium
analyzed the overlap of disease-associated SNPs from the NHGRI GWAS catalog with TFBS
and DNase I hypersensitivity sites [1]. A recent study integrated ENCODE data, among
other sources of functional data, into a model that selects optimally informative annotation
filters to improve SNP association studies [26]. Another study concluded that GWAS SNPs
embedded in cis-regulatory elements from disease-relevant cell types are likely to function
as eQTLs [27]. However, these studies do not provide a systematic method for integrating
all of the above-mentioned types of genomic data so as to determine candidate regulators of
phenotypic variation. Our study aims to address this issue by developing a computational
method named GENMi (Gene Expression iN the Middle) that integrates ENCODE TFBS,
genotype, gene expression and drug induced cytotoxicity data in LCLs to quantify the asso-
ciation between a TF and drug response, thereby elucidating putative regulators responsible
for observed cellular responses to drugs.
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1.2 PROBABILISTIC GENE EXPRESSION IN THE MIDDLE (PGENMI)
In this study, we develop a new probabilistic model, called pGENMi, that integrates
multi-omic data to investigate the transcriptional regulatory mechanisms underlying inter-
individual variation of a specific phenotype - that of cell line response to cytotoxic treatment.
In particular, pGENMi simultaneously analyzes genotype, DNA methylation, gene expres-
sion and transcription factor (TF)DNA binding data, along with phenotypic measurements,
to identify TFs regulating the phenotype. It does so by combining statistical informa-
tion about expression quantitative trait loci (eQTLs) and expression-correlated methylation
marks (eQTMs) located within TF binding sites, as well as observed correlations between
gene expression and phenotype variation. Application of pGENMi to data from a panel of
lymphoblastoid cell lines treated with 24 drugs, in conjunction with ENCODE TF ChIP
data, yielded several known as well as novel (TF, Drug) associations. Experimental valida-
tions by TF knock-down confirmed 41% of the predicted and tested associations, compared
to a 12% confirmation rate of tested non-associations (controls). Extensive literature survey
also corroborated 62% of the predicted associations above a stringent threshold. Moreover,
associations predicted only when combining eQTL and eQTM data showed higher precision
compared to an eQTL-only or eQTM-only analysis using pGENMi, further demonstrating
the value of multi-omic integrative analysis.
1.2.1 BACKGROUND
There is great interest today in understanding why certain drugs are effective in some
individuals but less so in others. Many studies have sought to identify mechanisms of ac-
tion of specific drugs [28, 29, 30] as well as genotypic variations that are predictive of an
individuals drug response [31, 4, 32]. A major class of drugs of interest today are cytotoxic
drugs that may be used in cancer treatment. Large scale data generation efforts, including
genotypic and molecular profiling of panels of cell lines [33, 34] along with drug response
(cytotoxicity) measurement on those cell lines [33, 35, 36], are expected to facilitate future
advances in cancer pharmacogenomics. As the diversity of such data sets increases, it is
important to devise rigorous computational methods that can combine these diverse data in
a principled manner to help scientists answer mechanistic as well as therapeutic questions
pertaining to drug response. For instance, correlating gene expression and drug response in
a panel of cell lines helps identify cytotoxicity-related genes [36] but it is not clear how one
might extend the approach to additionally exploit genotype (SNP) and epigenotype data
(e.g., CpG methylation marks) to maximum effect. We need a statistically sound approach
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capable of modeling phenotypic variation while integrating several heterogeneous genomic
and epigenomic data types. Additionally, despite numerous efforts to connect phenotype
with genotype and regulatory elements, there has not been a systematic effort to aggregate
such connections to learn major regulatory mechanisms underlying the genotype-phenotype
relationship and its variation across individuals. Furthermore, the regulatory impact of epi-
genetic sources of variation (for instance CpG methylation) are usually assessed in isolation
of genetic variants (SNPs). Recent studies have shown that there may be a complex interplay
between genetic, epigenetic, and transcriptional variation in relation to disease [37], arguing
for a more integrative approach to their analysis.
We present here a novel, statistically principled approach to aggregating data on genetic
as well as epigenetic variations, along with genome-wide profiles of regulatory function,
to derive associations between a transcription factor and individual variation in cytotoxic
response to a drug; this permits a mechanistic interpretation of the impact of molecular
variants on drug response. There have been new insights into how TFs may be regulated
by small molecules [38, 39], and there is no doubt as to their significance in human dis-
eases such as cancer [40, 41, 42]. Our aim therefore is to push the frontier of knowledge
regarding the relationship of TFs and drug response for putative therapeutic benefit. Our
new computational method is based on a statistical formalism called probabilistic graph-
ical models (pgm) [43], which are among the most flexible and principled ways available
today for inference from heterogeneous and noisy data. Using a rigorous data pre-processing
pipeline in conjunction with this powerful framework, we demonstrate that the (TF, Drug)
associations predicted by the method are accurate, by showing that knock-down of the TF
affects sensitivity to the drug. The new method is also applicable to other studies where one
seeks mechanistic factors underlying individual variation in a quantitative phenotype in the
presence of genotype and epigenotype information.
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CHAPTER 2: GENMI
2.1 INTRODUCTION
This study, published in Nature Pharmacogenomics in 2016 [44] integrates gene expression,
genotype and drug response data in lymphoblastoid cell lines with transcription factor (TF)-
binding sites from ENCODE (Encyclopedia of Genomic Elements) in a novel methodology
that elucidates regulatory contexts associated with cytotoxicity. The method, GENMi (Gene
Expression iN the Middle), postulates that single-nucleotide polymorphisms within TF-
binding sites putatively modulate its regulatory activity, and the resulting variation in gene
expression leads to variation in drug response. Analysis of 161 TFs and 24 treatments
revealed 334 significantly associated TFtreatment pairs. Investigation of 20 selected pairs
yielded literature support for 13 of these associations, often from studies where perturbation
of the TF expression changes drug response. Experimental validation of significant GENMi
associations in taxanes and anthracyclines across two triple-negative breast cancer cell lines
corroborates our findings. The method is shown to be more sensitive than an alternative,
genome-wide association study-based approach that does not use gene expression. These
results demonstrate the utility of GENMi in identifying TFs that influence drug response
and provide a number of candidates for further testing.
2.2 METHODS
2.2.1 DATA COLLECTION
We obtained genotype, gene expression and drug response data on 95 Han-Chinese, 96
Caucasian and 93 African American lymphoblastoid cell lines from the Coriell Cell Repos-
itory (Camden, NJ, USA). Of these 284 individuals, 176 were females and 108 males, with
an average age of 33.44 years. The genotype data consisted of 1 344 658 germline SNPs.
Quality control analysis had already been performed on these SNPs, removing those that
deviated from HardyWeinberg equilibrium, were called 95% of the time or had minor allele
frequencies of 5%. Gene expression data consisted of 54 613 Affymetrix U133 Plus 2.0 Gene-
ChIP (Santa Clara, CA, USA) probes assayed for the 284 individuals, with raw expression
data being transformed using QUOTE GC robust multiarray averaging. Genotype and gene
expression data are available at the National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under SuperSeries acces-
7
Table 2.1: Treatments analyzed in this study grouped into classes based on pharmacological
similarity
Treatment Family
Paclitaxel Antimicrotubule
Agents (Taxanes)Docetaxel
Doxorubicin Topoisomerase
II Inhibitors (Anthracyclines)Epirubicin
Cytarabine (ara-C)
Nucleoside
Analogues
Gemcitabine
Triceribine (TCN)
6-Mercaptopurine (6MP)
Purine
Antimetabolites
6-Thioguanine (6TG)
Cladribine
Fludarabine
Carboplatin
Platinum
Cores
Cisplatin (CDDP)
Oxaliplatin
Everolimus
Mammalian Target of Rapamycin (mTOR) Inhibitors
Rapamycin (Sirolimus)
Arsenic
Singletons
(no drug pair)
Hypoxia
Metformin
Medroxyprogesterone Acetate (MPA)
Methotrexate (MTX)
N-acetyl-p-benzoquinoneimine (NAPQI)
Radiation
Temozolomide (TMZ)
sion no. GSE24277. These data were published in a study by Niu et al [24].
Drug response data were derived from dosage-response curves of 24 cytotoxic treatments
shown in Table 2.1. The phenotype, called EC50, represents the concentration at which
the drug reduces the population of LCL cells to half of the initial population. Data for 15
of the 24 treatments have been published in analysis in various studies conducted on these
cell lines; in particular, MPA, NAPQI, 6MP, 6TG, araC, oxaliplatin, carboplatin, cisplatin,
docetaxel, everolimus, gemcitabine, paclitaxel, metformin, radiation and rapamycin have
been analyzed in published studies [24, 45, 46, 47, 48, 49, 50, 51, 42]. Response data for the
following nine drugs have not been published: arsenic, cladribine, doxorubicin, epirubicin,
fludarabine, hypoxia, MTX, TCN and TMZ. Cytotoxicity assay was performed for every
one of these drugs using the LCL panel. After initial optimization, cells were treated with
a range of concentrations for any given drug tested, followed by incubation for 48 to 72h.
MTS cytotoxicity assays were then performed using Cell Titer 96 AQueous Non-Radioactive
Cell Proliferation Assay kit (Promega Corporation, Madison, WI, USA), followed by ab-
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sorbance measurement at 490 nm in a Safire2 microplate reader (Tecan AG, Switzerland).
Cytotoxicity phenotypes were determined by the best fitting curve using the R package drc
(doseresponse curve) (https://cran.r-project.org/web/packages/drc/drc.pdf) based
on a logistic model.
Experimental data on TF binding were retrieved from the ENCODE project [1]; specif-
ically, the clustered ChIP (version 3) tracks across 91 were used. ChIP tracks consisted of
the clustered ChIP peaks of 161 TFs. TF ChIP high occupancy target regions were removed
too.
Gene mappings to the Affymetrix arrays were obtained for the Affymetrix Human Genome
U133 Plus 2.0 array. ENSEMBL gene symbols were used as the gene reference of choice:
we used 55 038 ENSEMBL gene symbols that were annotated with at least one ENSEMBL
exon. Of the 54 613 probes assayed on the HG U133 Plus 2.0 array, 37 677 mapped to at
least one of the 55 038 ENSEMBL gene symbols.
Human triple-negative breast cancer cell lines, BT549 and MDA-MB231, were obtained
from the American Type Culture Collection (Manassas, VA, USA). BT549 cells were cultured
in RPMI-1640 containing 10% fetal bovine serum. MDA-MB-231 cells were cultured in L-15
medium containing 10% fetal bovine serum.
2.2.2 DATA PROCESSING
REMOVING HIGH OCCUPANCY TARGET (HOT) REGIONS
We used TF ChIP peaks to focus on SNPs whose association with expression might be
mediated by the regulatory action of that TF. However, it is well known that different TFs
tend to co-localize at the same genomic loci, a phenomenon that is especially pronounced
at HOT (high occupancy target) regions, and a TFs binding at these HOT regions is not
necessarily indicative of regulatory function [52]. To enrich the ChIP-based collection of
binding sites for functional TF-DNA interactions, we removed segments of 50bp where six
or more TFs bind, resulting in a ∼ 25% reduction in the total number of ChIP TF peaks
across all ENCODE cell lines.
IMPUTATION PROCEDURE
Imputation was run separately for each race and chromosome separately. Chromosomes
were divided into 40MB regions. BEAGLE v3.3.1 was run on these 40MB regions of the
genome, plus a 1MB buffer region to the right and left of the main region, as the ends
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are generally imputed poorly. The reference and observed genotype data were inputted as
phased and unphased, respectively. The lowmem option was used to reduce the overall
amount of memory required to run BEAGLE; additionally, the excludemarkers option was
used to remove the rare SNPs from the reference mentioned above. For edification, BEAGLE
was only used to impute untyped markers, not missing genotyped markers.
PROCEDURE FOR COMPARING GENMI TO THE BASELINE METHOD
In order to compare the number of associations between GENMi and the baseline method,
we sought to randomly permute the data set presented to these methods so that we can esti-
mate their false positive rate (FPR). One way to create randomized data sets is to scramble
the gene expression to phenotype relationships. However, this kind of randomization is
meaningless for estimating FPRs of the baseline method as it does not incorporate gene
expression. We required a randomization procedure that allows us to present the same data
sets to both methods, thus using the same null distribution for estimating rate of Type 1
errors. Both methods utilized the following three types of information: TF binding sites,
genotype, and phenotype, and randomizing one of these three information types would be
suitable for defining a null distribution of data sets. We reasoned that permuting the bind-
ing locations of TFs would be a more appropriate permutation, as both methods attempt
to make the statement that co-location of TF binding locations with impactful SNPs is
not-random; randomizing where these peaks are located would destroy the TF-specific infor-
mation while keeping everything else unchanged and thus test whether the (TF, treatment)
associations discovered are indeed specific to the TF.
We randomized the locations of TF peaks by randomizing (SNP, TF peak) assignments,
while preserving the relative number of SNPs within each TFs DNA-binding regions, so that
it is the identity rather than the total number of SNPs co-locating with TF peaks that is
disrupted We segmented the set of all SNPs, X, into two disjoint sets. The first, Xcis (called
cis-SNPs), is the set of all SNPs within 50kb upstream of any Ensembl gene and represents
the set of all cis-SNPs. The second, Xtrans (called trans-SNPs), is the set of all SNPs not
located within any Ensembl gene: Xtrans = X − Xcis. For a given TF, we measured the
number of cis-SNPs, tcis, and trans-SNPs, ttrans within ChIP peaks of that TF. We then
generated 5000 random permutations by sampling tcis snps from the uniform distribution on
Xcis and ttrans SNPs from the uniform distribution on Xtrans. Not only does this destroy the
cis-regulatory architecture of a given TF, but it preserves the relative number of SNPs in
the cis context (which is important for GENMi) and ensures that each permutation selects
the same number of SNPs for a given TF.
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2.2.3 CONTROLLING FPR - GENMI TO EXPRESSION-LESS METHODS
For GENMi, the enrichment score (ES) computed by the GSEA procedure on a real data
set, for a specific (TF, treatment) pair, was compared to ES values from 5000 randomized
data sets for the same TF, thus providing the estimated FPR if this (TF, treatment) pair is
called significantly associated.
For methods without expression, we computed the cardinality of intersection between
GWAS SNPs with p-value ≤ 10−8 and the set of SNPs under a TFs peaks. This cardinality,
as observed on a real data set, for a given (TF, treatment) pair, was compared to the same
statistic observed in 5000 randomized data sets for the same TF, thus providing an estimated
FPR. Since this is done within each TF, this is equivalent to an empirical approximation to
the hypergeometric test p-value.
2.2.4 EXPERIMENTAL METHODS
All wet-lab experiments were performed in the laboratory of Dr. Liewei Wang at Mayo
Clinic, Rochester, MN. RNA interference and qRT-PCR. The small interfering RNAs (siR-
NAs) for the candidate transcript factors and negative control siRNA were purchased from
Dharmacon (Lafayette, CO, USA). Reverse transfection was performed in 96-well plates.
Specifically, 3000− 4000 cells were mixed with 0.1 ml of lipofectamine RNAi-MAX reagent
(Invitrogen, Grand Island, NY, USA) and 10 nM siRNA for each experiment.
Total RNA was isolated from cultured cells transfected with control or specific siRNAs
with the Qiagen RNeasy kit (QIAGEN, Valencia, CA, USA), followed by real-time quanti-
tative reverse transcription-PCR (qRT-PCR) performed with the one-step, Brilliant SYBR
Green qRT-PCR master mix kit (Stratagene, Santa Clara, CA, USA). Specifically, primers
purchased from QIAGEN were used to perform qRT-PCR using the Stratagene Mx3005P
Real-Time PCR detection system (Stratagene). All experiments were performed in trip-
licate with β-actin as an internal control. Reversetranscribed Universal Human reference
RNA (Stratagene) was used to generate a standard curve. Control reactions lacked RNA
template.
MTS CYTOTOXICITY ASSAY
Epirubicin, doxorubicin, paclitaxel and docetaxel were purchased from Sigma-Aldrich
(Milwaukee, WI, USA). Drugs were dissolved in dimethyl sulfoxide and aliquots of stock solu-
tions were frozen at -80◦C. Cell proliferation assays were performed in triplicate at each drug
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concentration. Cytotoxicity assays with the lymphoblastoid and tumor cell lines were per-
formed in triplicate at each dose. Specifically, 90µl of cells (5× 103 cells per ml) were plated
into 96-well plates (Corning, Corning, NY, USA) [53] and were treated with 10µl of epirubicin
or doxorubicin at final concentrations of 0, 0.0156, 0.03125, 0.0625, 0.125, 0.25, 0.55, 1 and 2
µmol l-1. Similarly, cells were treated with paclitaxel or docetaxel at 0, 0.01, 0.1, 1, 10, 50, 100, 1000
and 5000 nmol l-1. After incubation for 72 h, 20 µl of CellTiter 96 AQueous Non-Radioactive
Cell Proliferation Assay solution (Promega Corporation) was added to each well. Plates were
read in a Safire2 plate reader (Tecan AG).
2.2.5 STATISTICAL ANALYSES
SUMMARIZING CYTOTOXICITY CURVES
Significance of the half-maximal inhibitory concentration (IC50) values between negative
control siRNA and gene-specific siRNA was determined by the two-tailed unpaired t-test.
STATISTICAL TESTING TF ROLE IN DRUG RESPONSE (GENMI)
We operationally defined the cis-regulatory domain of a gene as the 50-kb sequence up-
stream of the genes transcription start site. For any given TF, we assigned a TF-specific
cis-eQTL score to each ENSEMBL gene as follows:
1. Retain all SNPs located in TF ChIP peaks in the cis-regulatory domain of the gene.
2. Retrieve all HG U133 Plus 2.0 probes mapped to the gene.
3. Compute the correlation (eQTL) for each (SNP, probe) combination. This is the
correlation coefficient, across all 284 cell lines, between the SNP genotype and the
probes expression value. Also, compute the P-value corresponding to this correlation
coefficient.
4. Use the coefficient of determination of the single best eQTL among all (SNP, probe)
combinations as the TF-specific cis-eQTL score of the gene. Retain probe and SNP
identities contributing to the best eQTL for further analysis.
We then considered the set of 400 genes with the strongest TF-specific cis-eQTL scores (we
additionally required that a gene included in this set have a TF-specific cis-eQTL P-value
≤ 0.05, so the cardinality of the set may be ≤ 400). These may be thought of as genes where
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genotypic variation in the TFBS correlates with variation in the genes expression, potentially
implicating the TF in their expression variation. Although SNPs outside of TFBS can affect
TF regulation of gene regulation [50] (for example, SNPs in cofactor binding sites), we limit
analysis to eQTL SNPs enveloped within TFBS, as the functional effect of SNPs distant
from the TFBS is not well understood. We therefore refer to this gene set as the eQTL gene
set of TF. In addition, we required that in order for us to analyze the role of TF in drug
response, there should be at least 15 genes with strong eQTLs within binding sites of that
TF, that is, the eQTL gene set of TF should have at least 15 genes, as per recommendations
accompanying the Gene Set Enrichment Analysis (GSEA) tool. This resulted in the analysis
being restricted to 114 of the 161 TFs for which ChIP data were available.
To determine whether the genotype expression associations identified above are linked
to the varying response to a given cytotoxic treatment (drug or radiation), we correlated
each probes expression value with the EC50 value of the treatment, and ranked all genes by
this correlation coefficient. (We used the best correlation coefficient among multiple probes
for each gene.) Using GSEA [54], we tested for statistical association between this ranked
list and the eQTL gene set of TF defined above. The GSEA procedure reported a P-value
that served as the basis for inferring a role for the TF in individual variations in response
to the specific cytotoxic treatment. As 114 TFs were separately tested in this manner, we
relied upon the false discovery rate (FDR) values reported by GSEA to correct for multiple
hypothesis testing with each treatment. We refer to this method as GENMi.
2.3 RESULTS
2.3.1 INTEGRATING GENO/PHENO-TYPE -EXPRESSION & ENCODE DATA
The relationship between genotype and response to cytotoxic treatments is expected to be
mediated, at least in part, by regulation of gene expression [17] (Figure 2.1A). Inclusion of
expression data in the LCL data set allows us to investigate this hypothesis by simultaneously
examining the correlation between genotype and expression and that between expression and
phenotype (Figure 2.1B). We hypothesized that SNPs manifesting the genotypeexpression
correlation (eQTLs) should reside within binding sites of TFs that orchestrate the transcrip-
tional programs activated or deactivated by the treatment, and that these SNPs influence
phenotypic variation through their effect on gene expression [55].
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Figure 2.1: (a) The GENMi (Gene Expression iN the Middle) method. Shown is the 50
kb upstream region of a single gene, with transcription factor-binding site (TFBS; ChIP
peaks) in yellow, single-nucleotide polymorphisms (SNPs; circles) and their allelic state
(black or white) in a sample of seven individuals, as well as gene expression (blue bars on
right) and drug response EC50 values (orange bars on left) in these individuals. The gene
is scored in two ways: correlation of the best expression quantitative trait locus (eQTL)
SNP (green diamond) coincident with a TFBS and correlation of the genes expression with
drug response (these two correlations are illustrated by lines connecting the two correlated
variables). Integrating over all genes, testing the overlap between strongest eQTL genes
and genes associated with drug response (enrichment test, bottom) quantifies the extent to
which a TF is associated with drug response via cis-regulatory mechanisms. (b) Cartoon of
Gene Set Enrichment Analysis (GSEA) used as the enrichment test in GENMi. Genes are
ranked according to their correlation with drug response (gene GWAS). The analysis looks
at the extent to which a given gene set (in this case genes carrying the strongest eQTLs
coincident with the TFBS) are enriched near the top or bottom of the ranked list. Here, the
gene set is strongly associated with genes positively associated with drug EC50 values. (c)
Baseline method that does not use expression data. Shown are SNPs (columns) distributed
throughout the genome within TFBS (yellow peaks) and outside. Genome-wide association
study (GWAS) SNPs (green diamonds) correlated with drug response across individuals
(rows) are tested for enrichment with within-TFBS SNPs to determine whether a TF is
associated with drug response.
Our goal was to test the possibility that a TF mediates the individual-to-individual vari-
ation of gene expression that in turn leads to variation in cytotoxicity across cell lines. To
this end, we sought examples (Figure 2.1A) where a SNP inside the TFBS (ChIP peak)
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Figure 2.2: Significant (transcription factor (TF), treatment) associations. Shown are the
log-transformed false discovery rate (FDR) values for all associations meeting FDR ≤ 0.1.
The greenblue range refers to enrichment for genes whose expression negatively correlates
with cytotoxicity, and the yellowred range indicates enrichment of genes whose expression
positively correlates with cytotoxicity. The yellowred log-transformed FDR values are mul-
tiplied by negative 1, creating the 3 to 3 range in the legend enrichment. Anything with an
FDR ≥ 0.1 is shown as white.
correlates with the neighboring genes expression (cis-eQTL [56]), and that genes expression
correlates with drug response. To formalize this idea as a statistical test (Figure 2.1B),
we (1) first ranked genes by the correlation between their expression and the phenotype,
(2) separately identified a fixed number of genes (400 in tests reported here) that bear the
strongest response. cis-eQTLs within the TFBS and (3) finally used GSEA to test whether
the latter set of genes (step 2) is enriched near the top of the former ranked list (step 1).
In other words, we asked: when using the TFBS as the context, is genotype-to-expression
correlation reflected in expression-to-phenotype correlation? Note that step (1) is performed
independently of the TF, and does no hypothesis testing; it simply ranks genes by their
(expression) correlation with phenotype. Steps (2) and (3) test whether the cis-eQTLs in-
duced by a TF appear significantly frequently near the top of this phenotype-associated gene
list, thus suggesting a role for that TF in the association between genotypic and phenotypic
variation, with expression variation in the middle. We call this entire procedure GENMi.
2.3.2 TFS WITH POTENTIAL ROLE IN CYTOTOXIC VARIATION
We used the GENMi method to assign statistical significance, that is, P-value and FDR
to each (TF, treatment) pair. In total, drug induced cytotoxicity for 24 drugs were analyzed,
of which 9 were prepared specifically for this study.
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Table 2.2: Number of TFs associated with each treatment at an FDR of 0.1 using the GENMi
method.
Treatment # of associations
Paclitaxel 20
Docetaxel 5
Doxorubicin 16
Epirubicin 1
Cytarabine (ara-C) 35
Gemcitabine 5
Triceribine (TCN) 10
6-Mercaptopurine (6MP) 18
6-Thioguanine (6TG) 23
Cladribine 19
Fludarabine 13
Carboplatin 1
Cisplatin (CDDP) 10
Oxaliplatin 1
Everolimus 1
Rapamycin (Sirolimus) 0
Arsenic 18
Hypoxia 4
Metformin 3
Medroxyprogesterone Acetate (MPA) 24
Methotrexate (MTX) 70
N-acetyl-p-benzoquinone imine (NAPQI) 6
Radiation 2
Temozolomide (TMZ) 29
A total of 3864 pairs were tested (114 TFs ×24 treatments).
There are 334 associations at a threshold of FDR ≤ 0.10, involving 91 TFs and 23 treat-
ments (Table 2.2). Figure 2.2 shows all log2 transformed FDR values of any TF and drug
with a significant association. The 334 significant associations were distributed unevenly
across the treatments, with the drug Methotrexate (MTX) appearing in 70 of the 334 as-
sociations (21%), followed by Cytarabine (ara-C) and Medroxyprogesterone Acetate (MPA)
as the drugs with most TF associations (see Table 2.2).
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Table 2.3: Number of treatments associated for each of 91 out of 114 TFs at an FDR of 0.1
using the GENMi method.
TF # TF # TF # TF #
POLR2A 15 TFAP2C 5 RAD21 3 ZNF143 2
CTCF 13 ARID3A 4 SIN3A 3 CBX3 1
MYC 9 CHD2 4 SMC3 3 E2F1 1
FOS 8 MAX 4 TBL1XR1 3 GABPA 1
SPI1 8 MAZ 4 TCF7L2 3 GTF2F1 1
WRNIP1 8 SMARCB1 4 YY1 3 HDAC1 1
CHD1 7 STAT1 4 BHLHE40 2 HDAC2 1
ELF1 7 TEAD4 4 FOXA2 2 NR3C1 1
KAP1 7 USF1 4 FOXP2 2 SMARCA4 1
MTA3 7 BATF 3 HNF4G 2 SMARCC1 1
RELA 7 BCL3 3 IKZF1 2 TFAP2A 1
STAT5A 7 E2F6 3 IRF1 2 TRIM28 1
ZNF263 7 EBF1 3 KDM5B 2 ZBTB33 1
CEBPB 6 EGR1 3 MAFF 2 ZBTB7A 1
EP300 6 EZH2 3 MXI1 2 ZKSCAN1 1
FOSL2 6 GATA1 3 NFYB 2 ZNF274 1
FOXA1 6 GATA2 3 NR2F2 2
NFIC 6 JUN 3 REST 2
RUNX3 6 JUND 3 RFX5 2
ATF2 5 MAFK 3 RPC155 2
FOXM1 5 MBD4 3 SIN3AK20 2
HMGN3 5 PAX5 3 STAT3 2
NFATC1 5 PHF8 3 TAF7 2
RBBP5 5 PML 3 TBP 2
SETDB1 5 POU2F2 3 TCF3 2
The TFs with the most numbers of associations at FDR 0.1 (shown in Table 2.3) were
POLR2A, the largest subunit of RNA Polymerase II, and CTCF, a versatile regulator in-
volved in gene activation, repression, silencing and chromatin insulation [57]. We have reason
to believe (Figure 2.4) that these frequent associations involving general TFs that bind the
genome extensively are artifacts of our procedure, in conjunction with linkage disequilibrium
and the promiscuous DNA binding of these TFs. We ignored such associations in our follow-
up investigations. Also included in the six TFs with the most drug associations were MYC,
which plays an important role in reversing multidrug resistance [58], and FOS, a member of
the AP-1 complex that is linked to chemotreatment resistance [59].
We next examined the collection of statistically significant (TF, treatment) associations
for prior experimental evidence supporting them. To our knowledge, there is no standard
17
Table 2.4: Literature support for 20 significant (TF, treatment) associations at FDR (false
discovery rate) ≤ 0.1 where the TF (transcription factor) is associated with ≤ 5 treatments
and the treatment is associated with ≤ 10 TFs.
Association No. Treatment TF Literature Evidence
1 Cisplatin EGR1 Direct
2 Cisplatin STAT1 Direct
3 Docetaxel FOXM1 Direct
4 Radiation STAT3 Direct
5 Cisplatin SMARCB1 Direct
6 Cisplatin BCL3 Direct
7 TCN EZH2 Indirect
8 Gemcitabine SETDB1 Indirect
9 Docetaxel KDM5B Indirect
10 Hypoxia ARID3A Indirect
11 Carboplatin MBD4 Indirect
12 Cisplatin TFAP2C Indirect
13 Docetaxel BCL3 Indirect
14 Everolimus TAF7 None
15 NAPQI TFAP2C None
16 TCN ARID3A None
17 TCN STAT1 None
18 Metformin HMGN3 None
19 Metformin ZKSCAN1 None
20 TCN SETDB1 None
benchmark that can help us with such an assessment, and hence we resorted to surveying
the literature for studies implicating a TF in the response to a specific cytotoxic treatment,
for example, TFs whose knockdown or overexpression has been shown to affect cytotoxicity,
though not necessarily in the lymphoblastoid cell line. We focused on significant (TF,
treatment) associations that are relatively unique, that is, the TF is associated with ≤ 5
(of 24) treatments and the treatment is associated with ≤ 10 (of 114) TFs. These 20
associations are shown in Table 2.4. We noted 6 of the 20 associations to be supported by
direct experimental evidence involving the drug and the TF. We discuss these below.
2.3.3 LITERATURE ASSOCIATIONS
DIRECT ASSOCIATIONS
Observation: FoxM1 (transcription factor forkhead box protein M1) is associated with
response to docetaxel. Remarks: overexpression of FoxM1 in gastric cancers was previ-
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ously shown to mediate resistance to docetaxel and inhibiting FoxM1 was found to reverse
docetaxel resistance in gastric cancers [60]. Similar conclusions were reached by other stud-
ies [61].
Observation:EGR-1 (early growth response protein 1) is associated with cisplatin treat-
ment. Remarks: EGR-1 has been shown to regulate cisplatin-induced apoptosis in human
esophageal squamous cell carcinoma cell lines (WHCO1) [62]. The EGR-1 promoter has
been shown to be induced by this drug [63, 64].
Observation: STAT1, a member of the signal transducer and activator family of tran-
scription factors, is associated with cisplatin. Remarks: overexpression of STAT1 in A2780
human ovarian cancer cells was shown to increase cisplatin resistance [65]. Moreover, inhibit-
ing STAT1 expression has been shown to attenuate cisplatin-induced ototoxicity in rats [66]
and mice [67].
Observation: STAT3, a homolog of STAT1 in the signal transducer and activator family
of transcription factors, is associated with radiation treatment. Remarks: a previous tudy
found STAT3 blockade to enhance radiosensitivity in Hep-2 cells [68]. Other studies have
reported that radiation activates STAT3 [69], and that targets of STAT3 are upregulated by
radiation in a mouse model of glioblastoma [70].
Observation: SMARCB1, a core component of the switch/sucrose nonfermentable (SWI/SNF)
nucleosome remodeling complex, is associated with cisplatin. Remarks: recent sequencing
of various cancer cells have demonstrated frequent mutations in SWI/SNF factors such as
ARID1A. Suppression of ARID1A and its paralog ARID1B sensitized the cell to cisplatin
as well as radiation. Suppression of SMARCB1 reproduced the same effects [71].
Observation: BCL-3 is associated with cisplatin. Remarks: a previous study found BCL-3
overexpression to suppress cisplatin-induced apoptosis in MCF7 breast cancer cell lines [72].
In addition to the above six examples of experimental results directly supporting an as-
sociation, we also noted seven of the statistical associations from Table 2.4 to be supported
by indirect experimental evidence involving transcriptional regulation of the TF in response
to the drug or direct experimental evidence involving a protein closely related to the TF,
shown below:
INDIRECT ASSOCIATIONS
The following seven (TF, treatment) associations were noted as having indirect support
from the literature, i.e., evidence that falls short of a direct manipulation of the TFs expres-
sion resulting in changed drug response.
Observation: KDM5B, a histone lysine demethylase, is associated with docetaxel. Re-
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marks: Interestingly, the KDM5B homolog KDM5A has been noted to have higher expression
in breast cancer patients with improved response to neoadjuvant docetaxel treatment [73].
The two closely related homologs KDM5B and KDM5A have been shown to highly con-
served mechanism of histone recognition and binding [74], and it is thus possible that the
statistical association discovered using ChIP data on KDM5B reflects the regulatory role of
KDM5A in docetaxel response.
Observation: The histone methyltransferase SETDB1 is associated with gemcitabine. Re-
marks: A recent study showed SETDB1 to be down-regulated by the action of p53 during cell
death induced by drug paclitaxel [75]. A different study showed that gemcitabine treatment
induces accumulation of p53 in cell lines [76], the two pieces of evidence together providing
indirect support for the noted statistical association.
Observation: ARID3A, a B-cell regulator of immunoglobulin heavy-chain transcription
(BRIGHT), is associated with hypoxia. Remarks: The micro RNA MiR-125b has been
shown to be significantly upregulated in endothelial cells under hypoxic conditions [77]. A
separate study using both murine and human B-cells shows that MiR-125b is a direct down
regulator of ARID3a and a plausible mechanism for resistance to apoptosis [78].
Observation: EZH2, a histone lysine methyltransferase from the mTOR/AKT pathway,
is associated triciribine. Remarks: Suppression of EZH2 has been associated with increased
sensitivity to chemotreatment in human hepatocellular carcinoma (HCC) cells [79].
Observation: MBD4, a DNA repair and methyl CpG binding protein, is associated with
carboplatin. Remarks: Previous studies found silencing of MBD4 to increased sensitivity
to oxaliplatin, a platinum treatment similar to carboplatin, in the HCT 116 and SW480
tumor cell lines [80]. Overexpression of MBD4 was found to alter colony survival upon
treatment with cisplatin, the parent compound of carboplatin, in a human colon carcinoma
cell line [81].
Observation: TFAP2C, a member of the Activating Protein 2 (AP-2) transcriptional
family, is associated with cisplatin. Remarks: siRNA knockdown of the homologous pro-
tein TFAP2A was previously shown to decrease cisplatin sensitivity in bladder cancer [82].
TFAP2-A and TFAP2-C share 76% similarity in their C terminal halves that harbor the DNA
binding domain and are known to bind to the GTGACGTCAG consensus motif 9113991 [83].
Observation: BCL-3, a proto-oncogenic transcription factor in B-cell lymphoma, is as-
sociated with docetaxel. Remarks: Docetaxel sensitivity has been found to increase upon
inhibition of NF-κB [84], which is a direct driver of BCL-3 expression [87]. Additionally,
overexpression of BCL-2, another B cell lymphoma proto-oncogene, was linked to docetaxel
sensitivity in small non-small cell cancer [85].
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Table 2.5: Associations from Table 2.4 with direct or indirect support, re-evaluated for
each sub-population (AA=African American, CA=Caucasian American, HCA=Han Chinese
American). P-values are shows for each sub-population, with and without the use of imputed
SNPs. P-values <= 0.05 are shown in bold.
P-val (no imputation ) P-val (imputation)
DRUG TF AA CA HCA AA CA HCA
CDDP EGR1 0.919 0.006 0.607 0.009 0.139 0.018
CDDP BCL3 0.654 0.320 0.010 0.891 0.125 0.005
CDDP SMARCB1 0.454 0.088 0.032 0.051 0.079 0.002
CDDP STAT1 0.072 0.645 0.787 0.884 0.675 0.889
CDDP TFAP2C 0.705 0.782 0.160 0.093 0.266 0.006
Docetaxel BCL3 0.265 0.677 0.514 0.035 0.012 0.283
Docetaxel FOXM1 0.010 0.000 0.396 0.000 0.065 0.851
Docetaxel KDM5B 0.004 0.738 0.304 0.000 0.001 0.135
Carboplatin MBD4 0.008 0.044 0.007 0.277 0.705 0.089
Gemcitabine SETDB1 0.092 0.085 0.058 0.590 0.247 0.137
Hypoxia ARID3A 0.511 0.015 0.018 0.386 0.300 0.117
Radiation STAT3 0.450 0.642 0.655 0.076 0.740 0.886
For seven of the associations noted in Table 2.4, we were unable to find strong sup-
porting evidence from the literature, making these promising candidates for future exper-
imental follow-up. To test the effects of imputation on these results, we replicated the
GENMi pipeline using both imputed and genotyped SNPs, to see how many of the literature-
supported associations in Table 2.4 were corroborated. The results are shown in Table 2.5.
Overall, imputation did not significantly alter the associations reported in Table 2.4: we
found 10 of the 13 associations with literature support reported in Table 2.4 to be recovered
in this new analysis at the nominal P-value threshold of 0.05 (FDR ≤ 0.13). In additionally,
form of literature support, 9 were significant in at least one sub-population, at a nominal
P-value of 0.05, using either the genotyped SNPs or genotyped as well as imputed SNPs.
2.3.4 POPULATION SPECIFIC ANALYSIS
We tested the effect of population stratification by repeating the genotyped SNP GENMi
and genotyped with imputed SNP GENMi analyses on each population separately. The
populations studied were Han-Chinese American (HCA, n = 95), African American (AA,
n = 93), and Caucasian American (CA, n = 96). Since we have three populations for
each analysis, we require that at least on population have the association at the requisite
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significance level. The nominal p-values for the genotyped SNP GENMi and genotyped with
imputed SNP GENMi analyses are located in Table 2.5. The results for each method are
discussed in the following sections.
For genotyped SNPs, a nominal p-value of 0.05 recovered 7 out of 13 associations. Specif-
ically, 4 out of 6 and 3 out of 7 of the direct and indirect associations. Three associations
were replicated across multiple populations: (Carboplatin, MBD4), (Docetaxel, FOXM1),
and (Hypoxia, ARID3A) in (AA, CA, HCA), (AA, CA), and (CA, HCA) respectively. The
other 4 associations were specific to populations: 1 association in AA, 1 association in CA,
and 2 associations in HCA.
Similar to the analysis using only genotyped SNPs, a nominal p-value of 0.05 recovered
7 out of 13 associations. Though carboplatin and hypoxia associations were lost when
including imputed SNPs, more associations for docetaxel and CDDP were gained, namely
with BCL3 and TFAP2C respectively. Two associations were replicated across multiple
populations: (Docetaxel, KDM5B) and (Docetaxel, BCL3) in (AA,CA) and (AA, CA). The
other 5 associations were population specific: 2 AA associations and 4 HCA associations.
2.3.5 SIMILAR METHOD SANS EXPRESSION REPORTS FEWER ASSOCIATIONS
To determine the utility of our method that integrates genotype, gene expression and
phenotype to identify (TF, treatment) pairs, we devised a baseline method agnostic of gene
expression. This baseline method (Figure 2.1C) tests whether GWAS SNPs (P-value ≤ 10−8)
for a given treatment are enriched within peaks of a particular TF, computing a P-value of
association for each (TF, treatment) pair. We sought to compare the number of significant
associations discovered by GENMi and the baseline method respectively at a fixed false
positive rate.
Table 2.6: Number of (TF, treatment) associations discovered by the GENMi method and
the baseline method that does not use expression data, at varying FPR threshold. The FPR
is estimated by running either method on 5000 randomized data sets where transcription
factor-binding site (TFBS) locations have been shuﬄed genome wide.
FPR 1 2× 10−1 2× 10−2 2× 10−3 2× 10−4
Baseline 1932 75 16 2 0
GENMi 2736 943 211 33 14
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Table 2.7: Shown are the functional validation results for 21 TFs enriched (at FDR 0.1 and
P-value ≤ 0.05) for either taxane, paclitaxel (PAX) or docetaxel (DOC).
GENMi Enrichments Cell Lines
PAX DOC MDA-MB-231 BTF549# TF
P-Value FDR P-Value FDR PAX DOC PAX DOC
1 BATF 0.0142 0.07 0.5160 1.00 UP UP
2 BCL3 0.4112 0.56 0.0020 0.03 UP UP UP UP
3 BHLHE40 0.0088 0.06 0.0487 0.30 UP UP
4 CEBPB 0.0024 0.02 0.3199 0.86 UP UP UP UP
5 ELF1 0.0020 0.03 0.0147 0.20 UP UP UP UP
6 FOS 0.0127 0.09 0.2007 0.63 UP UP
7 FOSL2 0.0285 0.12 0.0012 0.03 UP UP
8 FOXM1 0.2754 0.44 0.0052 0.07 UP UP UP
9 IKZF1 0.0213 0.09 0.1422 0.78 UP UP
10 KDM5B 0.0016 0.02 0.0004 0.04 UP UP
11 MAFK 0.0016 0.02 0.6006 1.00 UP UP UP UP
12 MTA3 0.0027 0.03 0.1556 0.62 UP UP UP
13 NFIC 0.0020 0.02 0.0131 0.18 UP UP UP UP
14 RBBP5 0.0012 0.02 0.3613 0.69 UP
15 REST 0.0008 0.04 0.2343 0.57 UP UP UP UP
16 SIN3A 0.0028 0.03 0.5193 0.78 UP
17 TBL1XR1 0.0071 0.04 0.5347 1.00
18 TCF7L2 0.0056 0.04 0.1004 0.45 UP
19 WRNIP1 0.0004 0.02 0.2273 0.59 UP UP UP
20 ZBTB33 0.0044 0.05 0.9282 0.95 UP UP
21 ZNF263 0.0168 0.09 0.0255 0.26 UP UP
Validation was performed in two triple negative breast cancer cell lines (BTF549 and MDA-
MB-231). For each cell line, drug and TF, a small interfering RNA (siRNA) knockdown
experiment was performed, followed by an MTA assay for the drug. Comparisons were
made to negative siRNA experiments to determine whether the TF decreased, increased or
did not affect the sensitivity of the cell to the drug. UP in the table refers to decreased
sensitivity or desensitization of the cell to the drug, that is, the TF knockdown increased
cell resistance/survivability to increasing concentrations of the apoptotic drug. In no case
was the knockdown found to decrease cell resistance. Cells with P-value ≤ 0.05 or FDR
≤ 0.1 are colored gray and represent the drug for which the TF was predicted to influence
response.
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Table 2.8: Shown are the functional validation results for 14 TFs enriched for either anthra-
cycline drug, epirubicin (EPI) or doxorubicin (DOX) at FDR 0.1 and P-value ≤ 0.05.
GENMi Enrichments Cell Lines
DOX EPI MDA-MB-231 BTF549# TF
P-Value FDR P-Value FDR DOX EPI DOX EPI
1 CBX3 0.0033 0.05 0.4734 0.77 UP UP
2 CHD1 0.0036 0.04 0.5706 0.82
3 E2F6 0.0051 0.06 0.0944 0.76
4 ELF1 0.0008 0.05 0.303 0.79 UP UP UP UP
5 HDAC1 0.002 0.04 0.9026 0.89 UP UP UP UP
6 HMGN3 0.0077 0.05 0.4534 0.76 UP UP
7 HNF4G 0.0004 0.03 0.5844 0.82 UP UP UP UP
8 MYC 0.1112 0.32 0.0028 0.09 UP UP UP
9 NR2F2 0.0112 0.08 0.8199 0.82 UP UP
10 POU2F2 0.0048 0.06 0.1192 0.72 UP UP
11 RBBP5 0.0004 0.04 0.7434 0.83
12 STAT1 0.0065 0.07 0.7122 0.87 UP UP
13 TEAD4 0.0101 0.07 0.8462 0.98
14 ZNF263 0.0071 0.05 0.1045 0.72 UP UP UP UP
Validation was performed in two triple negative breast cancer cell lines (BTF549 and MDA-
MB-231). For each cell line, drug and TF, a small interfering RNA (siRNA) knockdown
experiment was performed, followed by an MTA assay for the drug. Comparisons were
made to negative siRNA experiments to determine whether the TF decreased, increased or
did not affect the sensitivity of the cell to the drug. UP in the table refers to decreased
sensitivity or desensitization of the cell to the drug, that is, the TF knockdown increased
cell resistance/survivability to increasing concentrations of the apoptotic drug. In no case
was the knockdown found to decrease cell resistance. Cells with P-value ≤ 0.05 or FDR
≤ 0.1 are colored gray and represent the drug for which the TF was predicted to influence
response.
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Figure 2.3: (a) Dosage-response curves for the transcription factor (TF) NFIC across two
drugs, docetaxel (left) and paclitaxel (right), and two cell lines, MDA-MB-231 and BTF549.
Each plot shows significant increase in resistance to the drug upon knockdown of NFIC
compared with normal response of the cells, using a two-tailed paired t-test. (b) Dosage-
response curves for the TF ELF1 across two drugs, doxorubicin (left) and epirubicin (right),
and two cell lines, MDA-MB-231 and BTF549. Each plot shows significant increase in
resistance to the drug upon knockdown of NFIC compared with normal response of the
cells, using a two-tailed paired t-test.
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Figure 2.4: Six different gene loci are shown. The true regulator of the phenotype operating
through gene expression is illustrated as a yellow peak proximal to the TSS of a gene. A
general TF ChIP peak, important for gene expression and present for all transcribed genes,
is shown illustrated as a gray peak. An eQTL SNP affecting the regulators activity is shown
in green for each locus. Due to a linkage disequilibrium between markers in local proximity
(which is likely to be true for a 50kb cis-regulatory region), the non-eQTL SNPs, shown in
dark gray, within the general TFs peak is likely to replicate the signal of the eQTL SNP in
the true regulators peak due to linkage disequilibrium between markers in the same local
region which is a safe assumption for a 50kb cis-regulatory region. In this way, if the
regulator is associated with the drug response, the general TF will be as well since it is
essentially copying the regulatory signal from the true regulator.
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(a) Paclitaxel
(b) Docetaxel
Figure 2.5: Knockdown cytotoxicity dosage-response curves of 21 TFs with (A) paclitaxel
and (B) docetaxel drugs in the MDA-MB-231 triple negative breast cancer cell line. Con-
centration is measured in nM .
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(a) Paclitaxel
(b) Docetaxel
Figure 2.6: Knockdown cytotoxicity dosage-response curves of 21 TFs with (A) paclitaxel
and (B) docetaxel drugs in the BTF549 triple negative breast cancer cell line. Concentration
is measured in nM .
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(a) Epirubicin
(b) Doxorubicin
Figure 2.7: Knockdown cytotoxicity dosage-response curves of 14 TFs with (A) epirubicin
and (B) doxorubicin drugs in the MDA-MB-231 triple negative breast cancer cell line.
Concentration is measured in nM .
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(a) Epirubicin
(b) Doxorubicin
Figure 2.8: Knockdown cytotoxicity dosage-response curves of 14 TFs with (A) epirubicin
and (B) doxorubicin drugs in the BTF549 triple negative breast cancer cell line. Concen-
tration is measured in nM .
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For a fair comparison, we devised a procedure that generates randomized data sets and
asked whether either method discovers a significant association (a false positive, as the
data set is a randomized one) on it. By performing this test repeatedly and counting how
frequently each method (GENMi or the baseline method) reported false associations, we
were able to control for the false positive rate of each method in exactly the same manner.
The number of (TF, treatment) pairs reported by either method on the real data set, at each
false positive rate threshold, is shown in Table 2.6. The number of significant associations
found by the GENMi procedure far outweighs those in the baseline, indicating that utilizing
expression information improves the sensitivity of the association study.
2.3.6 IN VIVO EXPERIMENTAL VALIDATION OF TFS
We sought to verify whether TFs associated with drug response variation can be linked
in vivo to significant changes in cellular sensitivity to drug-induced apoptosis. Though we
utilized lymphoblastoid cell lines data for our association analysis, we performed siRNA
knockdown experiments in two different cell lines to demonstrate the generalizability of our
results and the LCL model system. Specifically, we choose two triple-negative breast cancer
cell lines, BTF549 and MDA-MB-231, that are of great clinical significance. In addition,
we restricted our analysis to two of the most widely utilized family of drugs used in the
treatment of breast cancer: anthracyclines (doxorubicin, epirubicin) and taxanes (docetaxel,
paclitaxel). In addition to being clinically relevant, the mechanisms of the drugs within each
family are very similar, gifting us with the ability to check self-consistency within a drug
family, that is, if TF increases resistance to doxorubicin, it should also increase resistance
to epirubicin. Cost and time constraints restricted the experimental validation in this study
to these four drugs.
To choose candidate TFs for validation, we restricted ourselves to those TFs that exhibited
a P-value of ≤ 0.05 and FDR of ≤ 0.1 for at least one drug in the family of interest. For
the taxanes, this produced 21 TFs, as shown in Tables 2.7 - 2.8 of which were omitted for
various reasons. For the anthracyclines, these criteria yielded 14 TFs, as shown in Table
2.4. CTCF and POLR2A were original candidates but omitted because they are ubiquitous
activators for expression. The siRNA knockdowns were performed for the 21 taxane- and 14
anthracycline-associated TFs with negative siRNA as a control.
Figures 2.5-2.8 show the results for each cytotoxicity experiment while Tables 2.7-2.8 show
the results of the assays for the taxanes and anthracyclines, respectively. Even though a TF
was tested even if it was predicted to be associated with only one of the two drugs in a family,
our definition of successful validation conservatively required a TF to affect significant change
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in the dosage-response curve for both drugs in the family. For additional stringency, this
requirement had to be met in both the tested cell lines. Using these stringent criteria, we
found 6 out of the 21 predicted TFs, specifically BCL3, CEBPB, ELF1, MAFK, NFIC and
REST, to increase resistance to taxane-induced cytotoxicity. An example of what constitutes
significant change (induced by a TF knockdown) in the dosage-response curve for the taxanes
is shown in Figure 2.3A, for NFIC knockdown. For the anthracyclines, we found 4 out of
the 14 predicted TFs, namely ELF1, HDAC1, HNF4G and ZNF263, to increase cytotoxic
resistance to doxorubicin and epirubicin in both tested cell lines. An example of a validated
TF association (ELF1) for the anthracyclines is shown in Figure 2.3B. The rest of the
cytotoxicity curves are shown in Figures 2.5-2.8. In addition, the GENMi analysis predicted
MYC to be associated only with epirubicin, and the experimental validation supports this
as it is associated only with epirubicin (in BTF549).
Although several of GENMi associations were not corroborated experimentally in both
drugs within a family and in both cell lines, this is expected to an extent as the selection of
TF knockdowns was based on GENMi predictions for either one of the drugs in the family
and made from a different cell line, that is, the experimental test was more stringent than
what the statistical association suggests. In total, we find the hit rates of 621 and 414
as significant evidence that GENMi identifies TFs that truly regulate cellular response to
drug-induced apoptosis.
2.4 DISCUSSION
We have presented a methodology for interrogating the extent to which specific TFs are
associated with individual variations in drug-induced cytotoxicity. We employ a statistical
approach that assumes cis-regulatory variants embedded within TFBS affect proximal genes,
whose varying expression is then reflected in drug response. Our approach is fundamentally
different from the triangulation approach in that we integrate TFDNA-binding data and are
able to associate TFs with drug response; also, we do not require the direct association of
SNPs with drug-induced phenotype. Focusing on drugs and TFs that feature in a limited
number of associations, we noted the statistically significant (TF, treatment) associations
to be frequently supported by the literature, in the form of experiments where knockdown
or overexpression of the TF changes drug response. Stringent control of the randomization
procedure illuminated the benefit of GENMi over a simple GWASTFBS overlap approach
where expression data are not used. Although our results showcase the true positive rate
of GENMi, they do not yet allow us to determine false negative rates or sensitivity because
of the absence of a comprehensive benchmark of true (TF, treatment) associations. Never-
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theless, our methods represent the first comprehensive methodology for assessing regulatory
associations with drug response.
There are several areas in which the GENMi method could be improved. For one, differ-
ences in allele frequencies between stratified populations has been shown to induce spurious
associations [86]; adjusting for this confounding factor in a more principled framework may
reduce the number of false positives in our results. Second, although filtering for ChIP high
occupancy target regions helps eliminate regions where it is difficult to assign function to any
one TF, one may not assume that all bound TFs are nonfunctional [52], and future extensions
of our method will be cognizant of this. The literature also indicates the existence of eQTL
hot spotseQTLs associated with a large number of genes as a result of various confound-
ing factors; elimination of the factors would aid in the discovery of true eQTL signals [87].
Another way of improving GENMi would be to exploit prior knowledge of the relationship
between drugs; relevant methods already exist, to an extent [88]. GENMi could also be
improved at the level of determining gene targets for a TF. At a statistical level, GENMi
reduces to a two-step procedure of enriching top cis-eQTL genes under a given transcrip-
tional regulatory context with genes whose expression correlates with a drug. Ideas from a
recent study that employs a two-step regressive framework to a similar end (but without the
integration of TF ChIP data)[17] may be adapted to eliminate the arbitrary threshold of
the GENMi method in determining transcription gene targets. In addition, GENMi could
be improved by considering more elegant eQTL models, such as the methods employed by
Sudarsanam and Cohen [89]; however, exploiting more complex methods capturing multi-
additive and epistatic interactions at the genome-wide level carries a heavy computational
price that is not easy to circumnavigate. Another area of investigation involves the deter-
mination of the cis-regulatory region: although cis-regulatory eQTLs are replicated better
across studies than trans-eQTLs [90], definitions of cis-regulatory regions differ widely [94].
In our analysis, we use an operational regulatory region size of 50 kb upstream of the genes
transcription start site; a size that has been used in many other studies [27, 91]. In fact,
studies have even used regions up to 100 kb [92]. In additionally, we denote the entire region
upstream of the gene as the de facto regulatory region of the gene. Together, these assump-
tions carry the risk that the regulatory region of one gene may contain regulatory sequences
for other genes; a more conservative regulatory size would dilute this effect, at the expense
of sensitivity. It is not known the extent to which different regulatory sizes and schemes
affect the GENMi analysis and more work needs to be conducted on this front. Enhancer
promoter interaction data from chromatin capture-based technologies such as Hi-C [93] will
help obviate this problem to a certain degree, though such data have to be obtained from
the cell type of interest. Furthermore, the GENMi method only considers single TFBS for
33
filtering eQTL SNPs; associations may be more conspicuous when considering combinations
of transcriptional contexts. Though this is hard to compute greedily, there are methods
for finding combinations of TFs overrepresented in cis-regulatory regions [94]. Additionally,
future work will benefit from analysis of protein QTLsSNPs correlated with protein abun-
danceas opposed to mRNA abundance [6, 93], as the activity of the gene at the protein level
is hypothesized to implement the target cellular response; however, genome-wide protein
data are not readily available. Finally, the GENMi method suffers from certain limitations,
as seen in Figure 2.4; linkage disequilibrium distributes the effects of casual SNPs in TFBS-
promoter interactions among many loci. For regulatory regions with a high incidence of
binding and strong cis-eQTL signal, it is likely that our schema for attributing target genes
to TFs will induce false positives (incorrect TF-gene interactions). Though at a single gene
level this may not be too significant, the GENMi method could still be improved by taking
into consideration the local LD environment, as well as the distribution of ChIP tracks in
that area. We leave this as future work however.
Our approach utilizing single TF contexts with eQTLs estimated from basal gene expres-
sion data in LCLs corresponds to a logical entry point analysis into the pharmacological
effects of TFs on drug response. To our knowledge, the GENMi approach is novel in its di-
rect interrogation of transcriptional regulation on drug-induced cellular response. Although
many improvements can be made, the fruit of the existing GENMi analysis in both our
literature review and control experiments illustrates the remarkable utility of the method.
In the next chapter, we detail the ways in which the GENMi method is extended into
a more flexible probabilistic formulation that accommodates multiple types of regulatory
evidence.
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CHAPTER 3: PGENMI
3.1 INTRODUCTION
In this study, published in Genome Research in 2018 [95], we capitalize on recent trends
in genomics to develop a model that integrates multiple types of -omic data to associate
TFs with drug response thereby extending the GENMi method from the previous chapter
into a more generalized model. Recent studies have analyzed large scale data sets of gene
expression to identify genes associated with inter-individual variation in phenotypes ranging
from cancer sub-types to drug sensitivity, promising new avenues of research in personalized
medicine. However, gene expression data alone is limited in its ability to reveal cis-regulatory
mechanisms underlying phenotypic differences. In this study, we develop a new probabilistic
model, called pGENMi, that integrates multi-omic data to investigate the transcriptional
regulatory mechanisms underlying inter-individual variation of a specific phenotype - that
of cell line response to cytotoxic treatment. In particular, pGENMi simultaneously analyzes
genotype, DNA methylation, gene expression and transcription factor (TF)-DNA binding
data, along with phenotypic measurements, to identify TFs regulating the phenotype. It does
so by combining statistical information about expression quantitative trait loci (eQTLs) and
expression-correlated methylation marks (eQTMs) located within TF binding sites, as well
as observed correlations between gene expression and phenotype variation. Application of
pGENMi to data from a panel of lymphoblastoid cell lines treated with 24 drugs, in conjunc-
tion with ENCODE TF ChIP data, yielded a number of known as well as novel (TF, Drug)
associations. Experimental validations by TF knock-down confirmed 41% of the predicted
and tested associations, compared to a 12% confirmation rate of tested non-associations
(controls). Extensive literature survey also corroborated 62% of the predicted associations
above a stringent threshold. Moreover, associations predicted only when combining eQTL
and eQTM data showed higher precision compared to an eQTL-only or eQTM-only analysis
using pGENMi, further demonstrating the value of multi-omic integrative analysis.
3.2 METHODS
3.2.1 DATA COLLECTION
We obtained data on single nucleotide polymorphisms (SNPs) , 3 mRNA probe expres-
sion, and CpG methylation status across 284 Epstein-Barr Virus (EBV) transformed lym-
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phoblastoid cell lines (LCL) from the Coriell Cell Repository. The ethnicities of the cohort
decomposed along the following three broad ethnic lines: 95 Han-Chinese American (HCA),
96 Caucasian American (CA), and 93 African American (AA). The sequenced genotype
data resulted in 1,362,404 germ line SNPs, each with minor allele frequency (MAF) ¡ 5%,
genotype rate ≥ 95%, and in Hardy-Weinberg Equilibrium. Imputation analysis of this
initial set of genotyped SNPs resulted in 11,256,504 SNPs. Gene expression data consisted
of 54,613 Affymetrix U133 Plus 2.0 Gene-Chip probes, transformed using log2 GC Robust
Multi-Array Averaging (GC-RMA). Genotyped SNP and gene expression data are available
in the NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo) under
SuperSeries accession no. GSE24277 and were originally published in a study by Niu et.
al [24]. We used data on 444,797 methylation marks, originally published by Heyn et al [96],
available in NCBI GEO under SuperSeries accession no. GSE36369. As a representation
of methylation status, we used the beta value, which encodes methylation status within [0,
1], where 0 and 1 correspond to total absence and presence of the mark respectively. Infor-
mation on pre-processing and analysis of this data including SNP imputation, population
stratification, gene expression processing, regression design, among others, resides in further
in Methods section for this chapter.
Drug response data was derived from dosage-response curves of 24 cytotoxic drugs: 6-MP,
6-TG, Ara-C, arsenic, carboplatin, cisplatin, cladribine, docetaxel, doxorubicin, epirubicin,
everolimus, fludarabine, gemcitabine, hypoxia, metformin, MPA, methotrexate, NAPQI,
oxaliplatin, paclitaxel, radiation, rapamycin, triciribine, and temozolomide. Each response
curve was summarized by an EC50 value (drug concentration at which half the original
LCL population survived treatment). These data were most recently analyzed by Hanson
et al. [44] and are available at the following location: veda.cs.uiuc.edu/cytotoxicity. Full
information regarding the experimental validation design, data, methodology, and statistical
analysis is discussed further in this chapter.
Experimental data on TF binding were obtained from the ENCODE project [1]. The
union of Clustered ChIP (v3) tracks of 161 TFs across 91 cell lines formed a single track for
each TF, representing a TF composite regulatory profile reflective of activity across a wide
variety of cellular contexts. The data for these clustered ENCODE cell lines are located
at the following URL: http://hgdownload.cse.ucsc.edu/goldenpath/hg19/encodeDCC/
wgEncodeRegTfbsClustered. We remove clustered peaks that were likely the artifact of high
occupancy target (HOT) regions, as in the GENMi analysis [44]. Contrary to that work,
we exempted the following 13 TFs from the full 161: general TFs (POLR2A, POLR3A,
POLR3G, TBP) and those for which no eQTL or eQTM SNPs (p < 0.05) were detected
within ChIP peaks (BDP1, BRCA1, BRF1, ELK1, ELK4, ESRRA, HSF1, KDM5A, NELFE).
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Further processing of this data, including the removal of High Occupancy Target (HOT) re-
gions, is described in further in this chapter.
3.2.2 TWAS, EQTL, AND EQTM ANALYSIS
Each of the following regression analyses controlled for the following covariates: sex, age,
batch, and population axes of variation derived from EIGENSTRAT. Transcript wide as-
sociation analysis, or TWAS [97], and eQTL analysis were performed following [44]. To
perform TWAS, we computed partial regression coefficient p-values between gene expression
and drug EC50 values across the 284 LCLs, for each (gene, drug) pair. For eQTL analysis,
we calculated partial regression coefficient p-values between each genes expression and the
genotype (measured by allelic dosing of 0,1,2) of each SNP in its cis-regulatory (50 Kbp
upstream) region. To avoid the statistical artifacts of linkage disequilibrium, we preserved
only the most significant eQTL-SNP in each genes cis-regulatory region. For eQTM anal-
ysis, we repeated the eQTL analysis while substituting SNP genotypes with methylation
status, a continuous variable between 0 and 1 representing the probability of the presence of
a CpG methylation, and thus computed eQTM (methylation to gene expression regression)
p-values, again retaining only the most significant eQTM in the cis-regulatory region of a
gene.
3.2.3 PROBABLISTIC MODEL INTEGRATES GENO/PHENO-TYPE WITH
EXPRESSION
OVERVIEW
In our previous work, we presented a proof-of-principle method that identifies TFs associ-
ated with individual variation in drug response or any other quantitative phenotype [44].We
searched for cases where a SNP in the cis-regulatory region of a gene is correlated with the
genes expression (cis-eQTL analysis) and the genes expression is correlated with phenotype
- the latter being referred to as a transcriptome wide association study (TWAS) [97]; if
significantly many cases like this were identified involving SNPs within ChIP peaks of a TF,
then the TF was considered associated with individual variation in phenotype. Here, we
constructed a rigorous probabilistic model that builds upon this idea to identify phenotype-
related TFs.
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Figure 3.1: Plate diagram of pGENMi model. A latent variable zg represents whether a gene
g mediates the influence of a TF on phenotype, and its enclosing rectangle denotes G such
genes. pg denotes the TWAS p-value between the genes expression and phenotype variation,
for or each of the G genes. If zg = 1, we expect an enrichment for significant TWAS p-values,
and pg is modeled by a Beta distribution parameterized by α; otherwise, pg is modeled as
being distributed uniformly in [0,1]. We also observe one or more lines of evidence supporting
the TFs influence on the expression of each gene g, such as the existence of a cis-eQTL within
a ChIP peak of the TF near that gene. These regulatory evidences are denoted by the binary
variables rgm, and there exist M such types of evidence (m = 1 . . .M), with relative weights
wm. These evidences combine in a logistic function to determine Pr(zg = 1). The weights
wm are learned over all genes, and as such, are shown outside of the rectangle enclosing G.
The H variable indicates whether wm is free or restricted to 0 (null model), for hypothesis
testing.
The new method is called pGENMi (the previous tool was named GENMi for gene ex-
pression in the middle and the p denotes a probabilistic model). It integrates information
from many genes whose expression correlates with the phenotype, and for which it can find
evidence supporting regulatory influence of a specific TF. The probabilistic formulation of
pGENMi offers the following important features:
1. It integrates gene expression-phenotype association without relying on strict thresh-
olds.
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2. As evidence for a TFs role in gene expression variation, it can utilize information about
different types of expression-linked cis-variants (genetic as well as epigenetic) located
in the TFs binding sites near the gene.
3. In incorporating multiple sources of evidence for a TFs regulatory role, it can weight
the contribution of each type of evidence differently, learning these relative weights
automatically.
The probabilistic model of pGENMi is described in Figure 3.1, but we present the main
ideas here. The model is evaluated separately for each TF and provides a log likelihood ratio
score to quantify the TFs role in regulating phenotypic variation, considering all available
data. It assigns to each gene g a hidden variable zg that takes a value of 1 if the gene g is
a mediator of the TFs influence on the phenotype, and 0 otherwise. The case of zg = 1 is
supported if the genes expression is correlated with the phenotype (TWAS p-value close to
0), and one or more lines of evidence support the TFs role in regulating that gene. Such
regulatory evidence may include the existence of a significant cis-eQTL within the TFs ChIP
peak located near the gene. Specifically, the probability of zg = 1 is determined by a linear
combination of one or more regulatory evidences, using a single free parameter as the relative
weight of each type of evidence. Intuitively, a TF is considered as a potential regulator of
the phenotype if the data supports the existence of several genes mediating its influence on
the phenotype, as reflected in their zg variables.
PGM
The pGENMi plate diagram is shown in Figure 3.1, which models the association between a
specific TF and a phenotype. There are four variable types (p, zg, rgm,H) and two parameter
types (α,wm). The variable rgm is a binary indicator variable representing whether a gene
g has a particular kind of evidence (e.g., cis-eQTL, cis-eQTM, etc.) of regulation by the
TF. Here, a cis-eQTL evidence is defined, following[44], as the presence of an eQTL within
a ChIP peak of the TF, in the 50Kb upstream region of the gene. Likewise, a cis-eQTM
evidence is the presence of an eQTM within a TF ChIP peak in the genes 50 Kbp upstream
region. Thus, if rgm = 1 for some gene g and m represents cis-eQTM evidence, we interpret
this as evidence that a change of TF binding at the ChIP peak is brought about by or
related to the observed individual variation in methylation status at the eQTM, which in
turn explains the latters correlation with gene expression.
A rectangle labeled with an M engulfs r, indicating that there are M such kinds of regula-
tory evidence for each gene g: rg1, rg2, . . . , rgM . Each rgm variable in a plate connects to the
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same zg variable. This latter variable is binary and latent (unshaded) and indicates whether
expression of a gene g is related to the phenotype. A rectangle labeled G encapsulates zg
and rgm, indicating that there is a latent variable zg and regulatory evidence vector rgm for
each of G genes. The state of zg is determined probabilistically, as:
P (zg = 1|rg1 . . . rgM , w0 . . . wM) = 1
1 + exp (−(w0 + w1rg1 + w2rg2 + . . . wMrgM)) (3.1)
Here, the various evidences rgm for the regulation of gene g by the TF are combined
in a logistic function, each weighted by a coefficient wm. Thus, a weighting of separate
regulatory evidences determines whether a gene g is related to the phenotype. The variable
p is a continuous variable in the range [0,1], representing the observed TWAS p-value (details
above) of the association between gene expression and phenotype. If a gene is related to the
phenotype (zg = 1), then we model p to follow a Beta(,1) distribution biased towards small
(significant) p-values; is a shape parameter indicating the strength of the bias, constrained
to the range [0,1], with =1 equivalent to a uniform distribution over p-values. However, if
a gene is unrelated to phenotype (zg = 0), we expect its expression-phenotype correlation
p-value to be uniformly distributed over [0,1]. These modeling assumptions are summarized
below:
pg ∼
{
Unif(0, 1), if zg = 0
β(α, 1), if zg = 1
(3.2)
The binary variable H indicates the hypothesis to be tested. When H=1, the model tries
to find the best assignments to w and ; this is the alternative hypothesis or H1. When
H = 0, the model only trains parameters w0 and α, and the weights w1 . . . wM are removed
from the model entirely. In this case, the model tries to explain the observed TWAS p-values
without any regulatory evidences at all; this is the null hypothesis, or H0. We derive a score
for how much better the alternative hypothesis explains the data y:
LLR = log2 P (y|A, H = 1)− log2 P (y|A, H = 0) (3.3)
The pGENMi method uses the log likelihood ratio (LLR), computed for each TF separately,
to rank TFs by their predicted association with the phenotype.
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PARAMETER ESTIMATION
The model uses the Expectation Maximization algorithm to find assignments to the pa-
rameters, w = [w0, w1, .., wM ] and α such that the likelihood of p = [p1, ..., pG] (observed
TWAS p-values) is maximized. The optimization imposes no constraints on the parameters,
and thus the weights of regulatory evidences (w) may be trained to negative values, in ef-
fect rewarding genes that have regulatory evidence but no expression-phenotype correlation;
this is inconsistent with our regulatory assumptions, and, as such, we post-process pGENMi
results to disregard such spurious TF-phenotype associations.
DETAILED DESCRIPTION
DEFINITIONS M = Number of regulatory evidences + 1.
G = Number of genes.
R = A matrix of size G×M , where the first columns is all 1s and each additional column a
binary corresponding to whether regulatory evidence was observed for that columns source.
rg := A vector of length M with the first column as 1 and each additional column a binary
corresponding to whether regulatory evidence was observed for that columns source.
w := A continuous vector of length M that weights each type of regulatory evidence. This
is a parameter estimated by the model across all genes.
zg := A binary latent variable representing whether or not the correlation p-value of gene
g’s expression with the phenotype of interest is drawn from a uniform or beta distribution.
α := Parameter determining the shape of the beta distribution. The β parameter is set
to 1 and α is capped in the range [0,1]. This parameter is estimated by the model.
pg := A continuous observed variable in the range [0,1] representing the correlation p-value
of gene g’s expression with the phenotype of interest
LIKELIHOOD
The probability that zg = 1 is a logistic function of w and rg:
Pr(zg = 1|w, rg) = 1
1 + exp (−w · rg) (3.4)
The probability that zg = 0 is 1−probability zg = 1:
Pr(zg = 1|w, rg) = exp (−w · rg)
1 + exp(−w · rg) (3.5)
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If you interpret 1 as exp(−0 ∗ rg), then this is simply the Boltzman distribution with the
2nd state being w = 0. The probability of pg depends on if zg is 1 or 0. With respect to the
former, it is distributed per a beta distribution (with β = 1) and uniform distribution for
the latter.
Pr(pg|zg = 1, α) ∼ β(α, 1) (3.6)
Pr(pg|zg = 0, α) ∼ Unif(0, 1) (3.7)
Aside:
Beta(α, 1) =
xα−1
β(α + 1)
=
xα−1
Γ(α)
Γ(α + 1) = α
Γ(α)
Γ(α)
xα−1 = αxα−1 (3.8)
Therefore,
Pr(pg|zg = 1, α) ∼ β(α, 1) = αxα−1 (3.9)
The likelihood of the data p given R is thus.
Pr(p|w,R, α) =
g∏
g=1
1∑
i=0
Pr(pg|zg = i, α)) Pr(zg = i|w, rg) (3.10)
Expanding the terms and the sum yields the following:
Pr(p|w,R, α) =
g∏
g=1
αpα−1g
1
1 + exp (−w · rg) +
exp (−w · rg)
1 + exp (−w · rg) (3.11)
The log likelihood is thus :
l(p|w,R, α) =
g∑
i=1
log
(
αpα−1g
1
1 + exp (−w · rg) +
exp (−w · rg)
1 + exp (−w · rg)
)
(3.12)
We can either optimize this function directly or use Expectation Maximization. In this
formulation, we choose EM.
POSTERIOR PROBABILITY
The posterior probability for zg = 1 is the following:
Pr(zg = 1|pg, α,w, rg) = Pr(zg = 1,pg, α,w, rg)
Pr(pg, α,w, rg)
=
Pr(zg = 1,pg, α,w, rg)
Pr(pg, zg = 0, α,w, rg) + Pr(pg, zg = 1, α,w, rg)
(3.13)
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Pr(pg, zg = 1, α,w, rg) = αp
α−1
g
1
1 + exp (−w · rg) (3.14)
Pr(pg, zg = 0, α,w, rg) =
exp (−w · rg)
1 + exp(−w · rg) (3.15)
Pr(zg = 1|pg, α,w, rg) =
αpα−1g
1+exp(−w·rg)
αpα−1g
1+exp(−w·rg) +
exp (−w·rg)
1+exp(−w·rg)
(3.16)
Pr(zg = 1|pg, α,w, rg) =
αpα−1g
αpα−1g + exp(−w · rg)
(3.17)
Naturally, the posterior probability for zg = 0 follows as 1−posterior probability of zg = 1:
Pr(zg = 0|pg, α,w, rg) = exp(−w · rg)
αpα−1g + exp(−w · rg)
(3.18)
EXPECTATION MAXIMIZATION
The function that EM optimizes is the Q(θ|θt−1) function where θ = w, α.It is essentially
the expectation of the joint log likelihood under the current parameters theta at time t with
respect to the posterior computed using the previous parameters θt−1.
Q(θ|θt−1) =
G∑
g=1
1∑
i=0
Pr(zg = 1|pg, αt−1,wt−1, rg) log Pr(pg, zg = i, α,w, rg) (3.19)
We will let the posteriors be designated as follows:
zt−1g0 = Pr(zg = 0|pg, αt−1,wt−1, rg) (3.20)
zt−1g1 = Pr(zg = 1|pg, αt−1,wt−1, rg) (3.21)
Expanding terms gives the following:
Q(θ|θt−1) =
G∑
g=1
zt−1g1 log (Pr(pg|zg = 1, α)× Pr(zg = 1|w, rg)) (3.22)
+ zt−1g0 log (Pr(pg|zg = 0, α)× Pr(zg = 0|w, rg)) (3.23)
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Further reducing gives:
Q(θ|θt−1) =
G∑
g=1
zt−1g1 log
αpα−1g
1 + exp(−w · rg) (3.24)
+ zt−1g0 log
exp(−w · rg)
1 + exp(−w · rg) (3.25)
Further reducing gives:
Q(θ|θt−1) =
G∑
g=1
zt−1g1 logαp
α−1
g − zt−1g0 (w.rg)− log(1 + exp(−w · rg)) (3.26)
UPDATES
When maximizing, we assume zt−1g0 and z
t−1
g0 are fixed. Therefore, finding a formula for w:
∂Q
∂w
=
G∑
g=1
rg ∗ ( exp(−w · rg)
1 + exp(−w · rg) − z
t−1
g0 ) (3.27)
Setting to 0 does not yield a closed form solution, so we use this gradient in a gradient
descent for updating w.
wt = wt−1 − β∂Q
∂w
(3.28)
For this study, we converge when:
||wt −wt−1||2 <  (3.29)
The parameter α has a closed form solution. Given
Q(θ|θt−1) =
G∑
g=1
zt−1g1 logαp
α−1
g − zt−1g0 (w.rg)− log(1 + exp(−w · rg)) (3.30)
Optimizing for α gives:
∂Q
∂α
=
G∑
g=1
zt−1g1
∂
∂α
(logα + (α− 1) log pg) (3.31)
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∂Q
∂α
=
G∑
g=1
zt−1g1 (
1
α
+ log pg) (3.32)
Setting to 0 and solving for α gives the following:
0 =
G∑
g=1
zt−1g1
1
α
+ zt−1g1 log pg (3.33)
−1
α
G∑
g=1
zt−1g1 =
G∑
g=1
zt−1g1 log pg (3.34)
α = −
∑G
g=1 z
t−1
g1∑G
g=1 z
t−1
g1 log pg
(3.35)
LOG LIKELIHOOD RATIO
We compare the fit model, H = 1, to a model where w = 0. We indicate this with, H = 0,
indicating the null hypothesis. We assess the significance of the alternative model, H = 1,
by computing the log likelihood ratio between a fit model and the null model.
LLR = log Pr(p|w,R, α,H = 1)− log Pr(p|w,R, α,H = 0) (3.36)
IMPLEMENTATION
In our implementation of EM, we choose β = 0.0001 and  = 0.0001 with a minimum
and maximum of 25 and 300 steps in each EM calculation and 100 random restarts for each
model. For each random restart, we estimated an alternative and null model. We report the
LLR corresponding to the model with the best log-likelihood for the alternative model.
TENSORFLOW IMPLEMENTATION
We also have a TensorFlow implementation available for download, although this imple-
mentation was not used to generate the results of this study.
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CODE LOCATION
Both the C++ code used to generate the results of this chapter and the TensorFlow code
are available in a GitHub repository located at https://github.com/knoweng/pgenmi and
with a link to the GitHub repository at veda.cs.uiuc.edu/pgenmi .
3.2.4 DATA PRE-PROCESSING AND STATISTICAL METHODOLOGY
REMOVING TFS FOR GENMI AND HOT REGIONS FROM ENCODE DATA
Some TFs (ATF1, BCLAF1, MEF2C, PPARGC1A, SMARCC2, STAT2) were filtered out
of the GENMi analysis for having an insufficient number of target genes (¡15) for GSEA. We
used TF ChIP peaks as a way to focus on SNPs whose association with expression might be
mediated by the regulatory action of that TF. However, it is well known that different TFs
tend to co-localize at the same genomic loci, a phenomenon that is especially pronounced
at HOT (high occupancy target) regions, and a TFs binding at these HOT regions is not
necessarily indicative of regulatory function [52]. To enrich the ChIP-based collection of
binding sites for functional TF-DNA interactions, we removed segments of 50bp where six
or more TFs bind, resulting in a ∼25% reduction in the total number of ChIP TF peaks
across all ENCODE cell lines.
SNP IMPUTATION
Imputation was run separately for each race and chromosome separately. Chromosomes
were divided into 40MB regions. BEAGLE v3.3.1 [98] was run on these 40MB regions of the
genome, plus a 1MB buffer region to the right and left of the main region, as the ends are
generally imputed poorly. The reference and observed genotype data were input as phased
and unphased, respectively. The lowmem option was enforced to reduce the overall amount
of memory required to run BEAGLE; additionally, the exclude markers option was used
to remove the rare SNPs from the reference mentioned above. For edification, BEAGLE
imputed untyped markers, not missing genotyped markers.
SUMMARIZING PROBE EXPRESSION BY GENE SYMBOL
Rather than modeling raw probe data, we opted to summarize probe level expression at
the Ensembl gene symbol level, since representing gene expression using multiple correlated
probes breaks the independence assumptions of our probabilistic model by giving greater
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weight to genes with higher probe coverage. Of the 54,613 probes, those with low variance
(σ2 ≤ 0.1), were omitted from analysis, purging 5,408 probes. Of the remainder, 34,832
probes mapped to 16,183 stable Ensembl gene symbols with at least one exon annotation,
using the GRCh37 Ensembl BioMart mapping of Ensembl gene symbols with HGU 133 Plus
2.0 array probe identifiers. Since multiple probes can map to the same gene, we utilized
a simple algorithm to obtain a single gene expression value as a function of its mapped
probe expressions. The following illustrates this procedure, which uses principle component
analysis (PCA) to obtain a vector of gene expression and Z-score normalization to ensure
all genes are scaled identically:
For each gene g with at least one mapped probe:
1. If g has one mapped probe
(a) Return z-score normalization of the probes expression.
2. If gene g has n mapped probes with a probe expression matrix of size n x 284:
(a) Obtain the first principal component (PC1) of the probe expression matrix.
(b) Project the probe expression matrix onto PC1.
(c) Return z-score normalization of the projected PC1 expression.
Applying this procedure resulted in a matrix of Ensembl gene expression with dimension-
ality 16,183 (number of genes) x 284 (number of LCLs), and Z-score normalized expression
across individuals. Henceforth in this publication, we refer to this matrix and its values as
the gene expression matrix and gene expression, respectively.
CONTROLLING FOR CONFOUNDING VARIABLES
We included the following potentially confounding variables as covariates in all regression
analyses for this study: batch, age, gender, and sub-population labels, derived from EIGEN-
STRAT (see below). We decided to omit explicit labels of ethnicity, as the sub-population
labels should capture that information implicitly. To derive p-values for the covariate of
interest in the multiple regression (for instance, a SNP in an eQTL regression) we computed
the p-value of the log likelihood ratio between models with and without the covariate of
interest, using a χ2 distribution.
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POPULATION STRATIFICATION
Despite the information provided by ethnic labels, it is well known that sub-population
structures within these ethnic groups contain important information that can radically con-
found the results of association analyses when ignored or improperly controlled [86]. To
address this issue, we utilized the EIGENSTRAT program (version 6.0.1) developed by
the Price lab (https://www.hsph.harvard.edu/alkes-price/software), to identify sub-
population labels from genotype data and remove their potential confounding effects in
regression analyses. Instrumental to EIGENSTRATs ability to recover true population la-
bels is the quality and format in which the data are provided. It may conflate large genomic
regions in linkage disequilibrium (LD) with population structure, hence such regions have
to be pruned. Additionally, while EIGENSTRAT could identify latent population labels
corresponding to the cohorts ethnicities from the entire cohorts genotype matrix, it is more
useful run EIGENSTRAT on each known ethnic groups genotype matrix: doing so will direct
EIGENSTRAT to look for sub-populations only within each ethnicity, and not across.
To perform this analysis, we first computed a set of independent SNPs using the PLINK
program (1.90 beta) [99]. For each ethnicity (HCA, CA, and AA), we used a variant pruning
algorithm to remove redundant SNPs in LD and reported only independent SNPs on somatic
chromosomes. To generate these results, we ran PLINK with the -indep flag and the following
parameters:
1. Window size (SNPs): 50
2. Shift window (SNPs): 5
3. Variance Inflation Factor (VIF) threshold: 1
Using these parameters, PLINK slides a window across the genome and only retains those
SNPs in the window that cannot be adequately predicted from a linear combination of the
remaining SNPs. For each SNP s in a window, PLINK reports a goodness of fit, R2s, of the
multivariate regression to predict s from all other SNPs. PLINK retains only those SNPs
with R2 >= 1 1
V IF
. Setting VIF to 1 ensures that only statistically independent SNPs in
each window are selected; although strict, this removes all potential for LD confoundment,
at the potential cost of underestimating the number of sub-populations.
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Table 3.1: Sub-population principal components extracted from EIGENSTRAT for each
ethnicity separately, with Tracy-Widom statistics and p-values.
# Ethnicity PC EigenValue EigenDiff TWStat P-Val Effect
1 CA 1 1.65 NA 60.84 2E-139 6767.46
2 CA 2 1.48 -1.72E-01 52.05 9.8E-111 9558.58
3 CA 3 1.25 -2.31E-01 18.28 1.58E-24 12486.00
4 CA 4 1.18 -7.04E-02 5.84 2.91E-06 13515.38
5 HCA 1 1.22 NA 9.94 6.74E-11 12980.28
6 AA 1 2.18 NA 73.83 9.9E-186 2955.53
7 AA 2 1.31 -8.68E-01 6.67 3.33E-07 5407.81
We estimated these sub-population labels as continuous axes of variation by using EIGEN-
STRAT to perform PCA on each ethnic groups independent SNP genotype matrix. Each
significant principle component (PC) derived from the genotype matrix of a given ethnicity
can be interpreted as a sub-population of that ethnicity. For each ethnicity, we retrieved
all PCs with Tracy-Widom p-values ≤ 0.05, resulting in a total of seven axes, shown in
Table 3.1. We projected the entire genotype matrix onto each of the seven axes (setting to
0 SNPs not contributing to the axis) to derive numeric sub-population representations for
the cohort. We included these sub-population labels as covariates in our regression models
to control for population stratification.
REMOVING COMMON TRANSCRIPTION FACTORS FOR EXPERIMENTS
In experimental validation, we avoided TFs like BRF2 and GTF2F1 that were associated
with 10 or more drugs. These are general transcription factors whose association is likely
due to having many more ChIP peaks than other TFs, a point we have discussed in previous
work [44]. We also excluded NAPQI, a toxic byproduct produced during the xenobiotic
metabolism of the analgesic paracetamol, due to its lack of clinical application.
CELL CULTURE AND TREATMENTS
All wet-lab experiments described in this chapter were performed in the laboratory of Dr.
Liewei Wang at Mayo Clinic, Rochester, MN.
Human triple negative breast cancer (MDA-MB231), leukemia (Jurkat), and glioma (U251)
cell lines were obtained from the American Type Culture Collection (Manassas, VA). MDA-
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MB-231 cells were cultured in L-15 medium containing 10% Fetal Bovine Serum (FBS).
Jurkat cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium, con-
taining 10% FBS. U251 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM),
also containing 10% FBS.
The following 10 drugs were purchased from Sigma-Aldrich (St. Louis, MO): 6-Mercaptopurine
(6-MP), 6-Thioguanine (6-TG), carboplatin, cisplatin (CDDP), cytarabine (Ara-C), doc-
etaxel, epirubicin, gemcitabine, oxaliplatin, and paclitaxel. The remaining three drugs were
obtained Selleck Chemicals (Houston, TX): cladribine, rapamycin (sirolimus), and temo-
zolomide (TMZ). All 13 drugs were dissolved in dimethyl sulfoxide (DMSO) and aliquots of
stock solutions were frozen at -80◦C.
siRNAs for candidate TFs and negative control siRNA were purchased from Dharma-
con. Reverse transfection was performed for MDA-MB231 and U251 cells in 96-well plates.
Specifically, 3000-4000 cells were mixed with 0.1 mL of lipofectamine RNAi-MAX reagent
(Invitrogen) and 10 nM siRNA for each experiment. Electroporation was performed for
Jurkat cells using Nucleofector Kit V from Lonza (Cologne, Germany).
Prior to electroporation, cells were washed with phosphate buffer saline (PBS) and counted.
One million Jurkat cells were re-suspended in 100 µL of the Nucleofector Solution buffer and
mixed with 100 nM of specific siRNA. The re-suspended cells were transferred to cuvettes
and immediately electroporated using the program X-005. After electroporation, cells were
incubated in a cuvette at room temperature for 10 minutes and then 500 L of pre-warmed
culture medium were added to the cuvette. Cells were then transferred to a 12-well plate
and incubated at 37◦C/5% CO2 overnight.
Total RNA was isolated from cultured cells transfected with control or TF-specific siRNAs
with the Qiagen RNeasy kit (QIAGEN, Inc.), followed by qRT-PCR performed with the
one-step Brilliant SYBR Green qRT-PCR master mix kit (Stratagene). Specifically, primers
purchased from QIAGEN were used to perform qRT-PCR using the Stratagene Mx3005P
Real-Time PCR detection system (Stratagene). All experiments were performed in triplicate
with beta-actin as an internal control. Reverse transcribed Universal Human reference RNA
(Stratagene) was used to generate a standard curve. Control reactions lacked RNA template.
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Table 3.2: Log (base 10) concentration of administered drugs applied during experimental
validation (- indicates no drug applied).
Drug Log10 Concentration
Scale
(mol/L)
µ n
Paclitaxel - -2 -1 0 1 1.7 2 3 3.7 4 x
Docetaxel - -2 -1 0 1 1.7 2 3 3.7 4 x
Epirubicin - -1.8 -1.5 -1.2 -0.9 -0.6 -0.3 0 0.3 0.6 x
Ara-C - -5 -4 -3 -2 -1 0 1 2 3 x
Gemcitabine - -5 -4 -3 -2 -1 0 1 2 3 x
6-MP - -2 -1 -0.3 0 0.4 0.7 1 2 3 x
6-TG - -2.3 -1.3 -0.6 -0.3 0 0.4 0.7 1.7 2.7 x
Carboplatin - -4 -3 -2 -1 0 1 2 3 4 x
Cisplatin - 0.1 0.4 0.7 1 1.3 1.6 1.8 1.9 2 x
Oxaliplatin - -0.5 -0.2 0.1 0.4 0.7 1 1.3 1.6 1.9 x
Cladribine - -4 -3 -2 -1 0 1 2 3 4 x
Rapamycin - -5 -4 -3 -2 -1 0 1 2 3 x
Temozolomide - -0.4 -0.1 0.2 0.5 0.8 1.1 1.4 1.7 2 x
MTS CYTOTOXICITY ASSAY
Cell proliferation assays were performed in triplicates at each drug concentration. Cyto-
toxicity assays with the lymphoblastoid and tumor cell lines were performed in triplicates at
each dose. Specifically, 90 L of cells (5 104 cells) were plated into 96-well plates (Corning,
NY) and were treated with increasing does of a specific drug or radiation. After incubation
for 72 hours, 20 L of CellTiter 96 R©. AQueous Non-Radioactive Cell Proliferation Assay
solution (Promega Corporation, Madison, WI) was added to each well. Plates were read in
a Safire2 plate reader (Tecan AG, Switzerland).
Cytotoxicity assays with the tumor cell lines were performed using the CellTiter 96 R©
AQueous Non-Radioactive Cell Proliferation Assay (Promega Corporation, Madison, WI).
Specifically, 90 L of cells (5 103 cells) were plated into 96-well plates and were treated
with increasing does of a specific drug. The escalation of log concentrations for each drug is
listed in 3.2. After incubation for 72 hours, 20 L of CellTiter 96 AQueous Non-Radioactive
Cell Proliferation Assay solution (Promega Corporation, Madison, WI) was added to each
well. Plates were read in a Safire2 plate reader (Tecan AG, Switzerland). Cytotoxicity was
assessed by plotting cell survival versus drug concentration, on a log scale.
Radiation cytotoxicity was performed in triplicates at each radiation dose as described
above. 100 L of cells (5 103 cells) were plated into 96-well plates and were treated with
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ionizing radiation at 0, 0.25, 0.5, 1, 2.5, 5, 10, and 20 Gy, using cesium-137 gamma-rays
(J.L. Shepherd and Associates Mark I Model 25 Irradiator). After incubation for 72 hours,
20 L of CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay solution was added
to each well. Plates were read in a Safire2 plate reader (Tecan AG).
STATISTICAL ANALYSIS
Significance of the IC50 values between negative control siRNA and TF-specific siRNA
was determined using a two-tailed unpaired t-test.
3.2.5 DATA ACCESS
Source code for pGENMi is available at the following:
https://github.com/knoweng/pgenmi
http://veda.cs.uiuc.edu/pGENMi/
3.3 RESULTS
3.3.1 PGENMI ELUCIDATES ROLE OF TFS IN DRUG RESPONSE VARIATION
We applied the pGENMi algorithm to identify TFs that putatively regulate individual
variation in drug response. We considered drug response data of 24 cytotoxic drugs (or
treatments) assayed on 284 lymphoblastoid cell lines (LCLs). This phenotypic data was
analyzed in conjunction with genotype (SNP), CpG methylation, and gene expression data
on the same panel of 284 LCLs, along with ENCODE ChIP-Seq data on TF-DNA binding.
To assess the regulatory evidence for a TFs role one a genes expression variation, we first
identified the strongest cis-eQTL SNP located near the gene (50Kb upstream of the tran-
scription start site) and within the TFs ChIP peaks; an eQTL p-value 0.05 was considered
as evidence for the TFs role in regulating the gene. We similarly tallied eQTM evidence,
i.e., a methylation mark significantly correlated with gene expression, located near the gene
(cis-eQTM) and within the TFs ChIP peaks. The eQTL and eQTM evidences for the TFs
regulatory influence on genes were then integrated with gene expression-phenotype associa-
tions (TWAS) using the pGENMi model. The result of this analysis is a ranking (by LLR
score) of all TFs by their predicted role in regulating each drug response phenotype. We
refer to this mode of analysis as eQTL+M analysis; we also repeated the entire procedure
using eQTL-only evidence and eQTM-only evidence
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In computing the various correlations (TWAS, eQTL, and eQTM) used in pGENMi anal-
yses, we included as covariates all information for which we had data per individual, i.e.,
sex, age, and batch, as well as sub-population axes of variation inferred from ethnic labels
and genotype information using EIGENSTRAT [89]; Also, we relied on clusters of TF ChIP
peaks from many different cell lines, as computed by the ENCODE project, rather than
peaks from LCLs exclusively. We believed this would make the regulatory inferences more
generalizable across cell lines and the ChIP peaks themselves more likely to be functional.
(See Tables 3.10 - 3.11 and Figure 3.4 a comparison to the alternative strategy of using TF
peaks exclusively from LCLs).
3.3.2 LITERATURE EVIDENCE
In the absence of a gold standard benchmark, we performed extensive literature search for
experimental results corroborating pGENMi-predicted (TF, Drug) associations, using two
criteria. The first, and most convincing, is direct experimental evidence demonstrating that
knockdown of the TF affects chemosensitivity to the corresponding drug. The second is
indirect experimental evidence demonstrating differential expression or DNA binding of the
TF induced by the drug.
Table 3.3: Literature support for the (TF, Drug) associations from pGENMi eQTL+M
analysis with LLR ≥ 4.5. There are three kinds of literature evidence: desensitization of the
cell to the drug as a result of a TF knockdown (“siRNA”), significant change in TF expression
(“Diff. Exp.”) or binding of the TF to the DNA (“Diff. Binding”) upon drug treatment.
“None indicates that we failed to find evidence of these three kinds in the literature.
# TF Drug LLR Literature Evidence PMID(s)
1 FOXM1 Temozolomide 7.4 siRNA 22977194
2 STAT3 Oxaliplatin 6.95 siRNA 22193989, 21472135, 24098947, 23969971
3 RELA Temozolomide 6.52 siRNA 23259744, 17638900
4 HNF4G Epirubicin 6.2 siRNA 26503816
5 HNF4G Doxorubicin 5.48 siRNA 26503816
6 BATF Docetaxel 5.57 siRNA 26503816
7 NANOG Cisplatin 4.62 siRNA 22714588
8 EZH2 Radiation 4.82 siRNA 25460508, 25601206
9 NFIC NAPQI 7.08 Diff. Expr. 17562736, 21420995, 17585979
10 GATA1 Rapamycin 5.78 Diff. Binding 10713726, 21304100
11 CCNT2 NAPQI 5.67 Diff. Expr. 21420995, 22230336
12 NANOG Oxaliplatin 5.46 Diff. Expr. 25979230, 26136074, 24462001, 24098947, 23585460
13 ZNF274 Ara-C 5 Diff. Expr. 17039268
14 UBTF NAPQI 4.8 Diff. Expr. 17562736
15 MEF2C NAPQI 7.17 None
16 CTCFL NAPQI 6.9 None
17 WRNIP1 6-MP 6.68 None
18 USF1 Temozolomide 4.69 None
19 NANOG 6-MP 4.51 None
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Figure 3.2: The 90 (TF, Drug) associations predicted by eQTL+M with LLR ≥ 3, colored by
LLR. Labels indicate whether eQTL-only or eQTM-only analysis corroborated the prediction
at LLR ≥ 1.74 (labels S and M respectively). A X indicates both eQTL and eQTM analysis
supported the prediction, while a - indicates the prediction is unique to eQTL+M.
Initially, we restricted our literature search to eQTL+M associations with LLR ≥ 4.5,
roughly corresponding to a p-value of 0.05 (χ2 test). Of the 19 reported associations at
this stringent criterion, 14 were validated by the literature (8 directly and 6 indirectly), as
shown in Table 3.3. For example, pGENMi reported FOXM1 as a top scoring association
for the drug Temozolomide; this prediction was validated by a study where siRNA knock-
down of FOXM1 was shown to sensitize recurrent glioblastoma multiforme (GBM) tumors
to this drug [100]. pGENMi also predicted STAT3 as being associated with response to
oxaliplatin. Indeed, siRNA silencing of STAT3 combined with oxaliplatin therapy, in mouse
models of metastatic colorectal cancer (HCT116), was previously found to reduce tumor size
better than either drug separately [101]. An example of indirect validation is that of the
predicted association between GATA1 and rapamycin. Treatment of hexamethylenebisac-
etamide (HMBA), which commits cells to cessation of growth and differentiation, to friend
erythroleukaemia cells increased DNA binding of GATA1, an important TF for erythroid
specific genes. When treated with the S6-kinase inhibitor, rapamycin, HMBA cells induced
at 18 hours showed markedly lower binding of GATA1 to the DNA [102].
Some drug responses may be easier to model using gene expression than others, due to
variation in the quality of experiments and different mechanisms of action. As such, we
sought to examine how literature-based validations of pGENMi associations segregate by
drug. To do this, we relaxed the LLR threshold to 3, which resulted in 90 (TF, Drug)
associations (Figure 3.2).
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Table 3.4: Literature support for predicted (TF, Drug) associations, separated by drug.
Shown are the number of predictions (P), true positive (TP), and precision of up to top 7
associated TFs with LLR geq3 for each drug. We call a predicted (TF, Drug) pair true if
there is direct or indirect literature evidence for it.
Drug P
TP
Precision
Direct Indirect
6-MP 7 0 1 1/7 14%
6-TG 4 0 0 0/4 0%
Ara-C 6 3 2 5/6 83%
Arsenic 1 1 0 1/1 100%
Carboplatin 1 1 0 1/1 100%
Cisplatin 7 5 2 7/7 100%
Docetaxel 1 1 0 1/1 100%
Doxorubicin 3 2 1 3/3 100%
Epirubicin 4 3 0 3/4 75%
Gemcitabine 5 0 1 1/5 20%
Hypoxia 1 1 0 1/1 100%
NAPQI 7 0 4 4/7 57%
Oxaliplatin 7 2 4 6/7 86%
Paclitaxel 3 1 1 2/3 67%
Radiation 4 4 0 4/4 100%
Rapamycin 3 3 0 3/3 100%
TCN 2 0 0 0/2 0%
Temozolomide 7 3 0 3/7 43%
We further restricted our literature survey to at most top seven associations for each drug
(to limit the burden of manual validation), amounting to 73 associations. The precision
(fraction of positive predictions supported by literature evidence) of these top associations
varies widely across drugs (Table 3.4). For certain drugs, such as cisplatin, all seven pre-
dictions were confirmed by direct or indirect literature evidence. We also observed 100%
precision for the following drugs for which a single TF was predicted:. On the other hand,
TFs associated with certain drugs, e.g., 6-MP and 6-TG, were rarely supported by the lit-
erature. Overall, our literature survey resulted in validation of 45 of 73 (62%) predictions
made at the modest threshold of LLR ≥ 3, but pointed to substantial inter-drug variability
in pGENMis ability to identify TF determinants of cytotoxicity.
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Table 3.5: Decomposition of the 90 (TF, Drug) associations with LLR >= 3 from eQTL+M
analysis by their significance in eQTL- and eQTM-only analyses.
eQTM-only
No Yes
eQTL
No 11 31
Yes 45 3
Table 3.6: Decomposition of the LLR ranks of eQTL and eQTM (TF, Drug) associations
with no thresholds applied.
A
eQTM
Top 500 Not Top
eQTL
Top 500 103 384
Not Top 397 2595
(a) Decomposition of the LLR ranks of eQTL
and eQTM (TF, Drug) associations with no
thresholds applied.
B
eQTM+M
Top 500 Not Top
eQTL
Top 500 309 161
Not Top 173 2765
(b) Decomposition of the LLR ranks of
eQTL and eQTL+M (TF, Drug) associa-
tions with no thresholds applied.
C
eQTM+M
Top 500 Not Top
eQTL
Top 500 262 223
Not Top 220 2703
(c) Decomposition of the LLR ranks of
eQTM and eQTL+M (TF, Drug) associa-
tions with no thresholds applied.
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We also assessed the benefit of modeling multiple types of regulatory evidence simulta-
neously (i.e., eQTL+M) rather than simply taking the union of associations reported by
running pGENMi for each evidence (eQTL or eQTM) separately. To answer this question,
we ran eQTL-only and eQTM-only analyses and applied an LLR threshold of 1.74 (roughly
corresponding to χ2 p-value of 0.05) for their reported associations. We then categorized the
90 eQTL+M associations with LLR≥ 3 (Figure 3.2) based on their recapitulation in eQTL-
and eQTM-only analysis (Table 3.5). Strikingly, the eQTL+M associations were rarely sup-
ported by both analysis. Despite this, 11 associations were identified by the eQTL+M model
that a simple intersection would not produce; we further investigated these associations in
our experimental validation. In looking at the top 500 (TF, drug) associations reported by
each analysis, we noted that the eQTL+M analysis and eQTL-only analysis showed strong
concordance (309 common associations), while the eQTM-only analysis showed much less
concordance with results from the other two analyses (see Table 3.6)
TOP 19 (TF, DRUG) ASSOCIATIONS
Here, we list and discuss the top (TF, Drug) associations predicted by eQTL+M with an
LLR ≥ 4.5 ranked by strength of evidence and LLR score (see Table 3.3). For each (TF,
Drug) association, we report several fields. The first is the “Validation Status” field, which
indicates whether we consider this association to be direct validation (exhibited usually by
TF knockdown) or indirect (exhibited usually by TF mRNA differential expression or binding
in response to the drug treatment). The second field, “Evidence”, summarizes the evidence
we found for the association. The next field, “LLR”, contains the pGENMi eQTL+M LLR
for the association. The following High Scoring Analyses field contains the experiments that
yielded a significant LLR; for eQTL and eQTM, the LLR threshold was 1.74. Since we
only examine significant eQTL+M pairs in this analysis, every association should at least
have eQTL+M in this field. The last field is Observation which is a paragraph describing
literature evidence we found corroborating the (TF, Drug) association or at least providing
some evidence as to its validity.
Association: FOXM1 with Temozolomide
Validation Status : Direct
Evidence: TF siRNA and Differential TF Concentration
LLR: 7.40
High Scoring Analyses : eQTL+M, eQTL, eQTM
Observation: Recurrent glioblastoma multiforme (GBM) tumors are characterized by a resis-
tance to chemo and radiotherapy. Recurrent GBM tumors resistant to temozolomide showed
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higher levels of FOXM1 than primary tumors. Treating GBM cell lines with temozolomide
increased expression of FOXM1 and the DNA damage repair gene, RAD51 and showed re-
sistance to temozolomide treatment. Knockdown of FOXM1 via siRNA assays inhibited
RAD51 expression and sensitized recurrent GBM to temozolomide. The regulatory rela-
tionship between FOXM1 and RAD51 was further corroborated by ChIP analysis showing
a preponderance of FOXM1 binding in the RAD51 promoter [100].
Association: MEF2C with
Validation Status : Not Validated (Some Evidence)
Evidence: Regulatory Partner of Differentially Expressed Drug Target mRNA
LLR: 7.17
High Scoring Analyses : eQTL+M, eQTL, eQTM
Observation: Yeast 2 hybrid experiments showed an interaction between MEF2C and HABP4;
further investigation showed that HABP4 inhibits the DNA binding potential of MEF2C.
This interaction was confirmed in-vitro using GST-pull down assays and in-vivo rat heart
cells by ChIP [103]. A separate study on hepatotoxicity demonstrated that acetaminophen
treatment affected HABP4 expression [104]. Given the interaction between MEF2C and
HABP4 and HABP4s sensitivity to acetaminophen, we concluded that though there may
be an association between MEF2C and NAPQI, we did not have sufficient experimental
evidence to call the relationship direct or indirect.
Association: NFIC, CCNT2, and UBTF with NAPQI
Validation Status : Indirect
Evidence: Differential Expression of TF mRNA
LLR: 7.08, 5.67, and 4.80 respectively
High Scoring Analyses : eQTL+M for all, eQTL for NFIC, and eQTM for CCNT2 and UBTF
Observation: A multi-center study of the effect of acetaminophen (APAP) toxicity to liver
cells showed differential expression of the TFs NFIC and UBTF to acetaminophen treat-
ment [108]. In a separate gene expression analysis of human liver slices, treatment of ac-
etaminophen also induced differential expression NFIC and CCNT2 [105]. The association
between NFIC and APAP toxicity was also established in mouse liver samples [106]. Finally,
a transcriptomic, proteomic, and metabolomics profile of hepatoma cells with and without
APAP demonstrated the differential CCNT2 expression [107].
Association: STAT3 with Oxaliplatin
Validation Status : Direct
Evidence: TF siRNA and Differential TF Concentration
LLR: 6.95
High Scoring Analyses : eQTL+M, eQTL
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Observation: In a study exploring the immune response of oxaliplatin treatment, researchers
showed that oxaliplatin decreased TLR-induced STAT1 and STAT3 expression in human T
cells via Western Blotting [108]. In mouse models of metastatic colorectal cancer (HCT116),
siRNA silencing of STAT3 combined with oxaliplatin therapy reduced tumor size by 96%,
better than either treatment separately (77% and 57% respectively) [101]. This interaction
between oxaliplatin and STAT3 was articulated in another study of HCT116 cells, where in
vitro treatment of oxaliplatin was accompanied with IL-6 mediated activation of STAT3 as
well as phosphorylation of Raf kinase inhibitor protein (RKIP) [109]. Work by Hua et al. in
SKOV3 ovarian cancer cell lines recapitulated this relationship in a different cell line, with
the conclusion being that oxaliplatin treatment upregulated STAT3β [110].
Association: RELA with Temozolomide
Validation Status : Direct
Evidence: TF siRNA and Differential Expression of TF mRNA Expression
LLR: 6.52
High Scoring Analyses : eQTL+M, eQTL
Observation: A previous study demonstrated that the DNA - methylating drug temozolo-
mide (temozolomide) activates the positive modulator of NF - B, AKT, in a mismatch
repair (MMR) system dependent manner. Mismatch repair systems are either proficient in
the repair of DNA double strands breaks (DSBs), or deficient, conferring chemosensitivity
to the former and chemoresistance to the latter. A subsequent investigation into whether
NF B is activated by temozolomide and whether AKT is involved in the molecular biology
of this event revealed several interactions between the NF B family member, RELA, and
temozolomide. Treatment of temozolomide to proficient MMR systems enhanced NF B
transcriptional activity, activated AKT, and induced RELA nuclear translocation in only
MMR-proficient cells. Upregulation of NF B transcription and RELA translocation were
impaired in KD12 cells treated with temozolomide and transfected with siRNA targeting
AKT. Additionally, RELA silencing in deficient MMR systems increased temozolomide-
induced growth suppression [111]. An examination of temozolomide inhibition of NF B ac-
tivity revealed that O6-methylguanine inhibits RELA DNA binding; Another study showed
differential RELA expression in response to temozolomide treatment in glioma cells [112].
Association: HNF4G with Epirubicin and Doxorubicin
Validation Status : Direct
Evidence: TF siRNA
LLR: 6.20 and 5.48 respectively
High Scoring Analyses : eQTL+M and eQTL for both
Observation: Our previous work demonstrated the link between the anthracyclines, epiru-
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bicin and doxorubicin, with HNF4G by using siRNA knockdown of HNF4G in two triple
negative breast cancer cell lines MDA-MB-231 and BTF459. The cytotoxicity curve of cell
population survivability versus the log concentration of epirubicin or doxorubicin treated
was significantly altered in both MDA-MB-231 and BTF459 when transfected with HNF4G
siRNA [44]: and compared to DMSO control experiments.
Association: GATA1 and Rapamycin
Validation Status : Direct
Evidence: Differential TF DNA Binding and siRNA
LLR: 5.78 High Scoring Analyses : eQTL+M, eQTM Observation: There is a close relation-
ship between the mTOR pathway, which rapamycin directly targets, and the PI3K share a lot
of crosstalk, leading to the development of dual inhibitors [113]. Research on the involvement
of phosphoinosite 3-kinases (PI3K) in cellular differentiation was investigated in the context
of friend murine erythroleukaemia cells. The early hours of dimethyl sulfoxide (DMSO) or
hexamethylenebisacetamide (HMBA) exposure to these cells commits them to a cessation
of growth and differentiation. Treatment of these inducers to friend erythroleukaemia cells
increased DNA binding of GATA1, an important transcription factor for erythroid specific
genes. When treated with the S6-kinase inhibitor, rapamycin, HMBA cells induced at 18
hours showed markedly lower binding of GATA1 to the DNA [106]. Together, this indicated
that rapamycin may inhibit binding of GATA1 to DNA via the PI3K dependent AKT/p70
S6-kinase pathway. Another study concluded that mammalian target of rapamycin (mTOR),
which is related to the aforementioned AKT pathway, tightly regulates GATA1 protein ex-
pression at the post-transcriptional level [114]. Yet another investigation into the role of
epidermal growth factor (EGF) on upregulation of the excision-repair cross-complementary
1 (ERCC1) gene in human hepatocarcinoma cells (HuH7) revealed that in EGF-induced
HuH7 cells, PI3K inhibition combined with silencing of the PI3K pathway kinase FKBP12-
rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) upregu-
lated ERCC1. Additionally, motif search identified a binding site for GATA1 in the promoter
of ERCC1 with ChIP confirming the binding of GATA1 to the promoter in EGF-induced
cells [115]. This indicates that GATA1 plays a role in mTOR/PI3K signaling, as it is a pos-
sible regulator of a target of such a pathway. Finally, this association was also corroborated
by our own siRNA knockdown of GATA1 in MDA-MB-231 cells treated with rapamycin;
cells were more resistant to rapamycin-induced apoptosis when GATA1 was knocked down.
Association: BATF with Docetaxel
Validation Status : Direct
Evidence: TF siRNA
LLR: 5.57
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High Scoring Analyses : eQTL+M
Observation: In the study by Hanson et al., the effect of BATF on the cytotoxicity of
paclitaxel and docetaxel on the triple negative breast cancer cell lines, BTF549 and MDA-
MB-231. Silencing BATF shifted both the cytotoxicity curves of paclitaxel and docetaxel in
MDA-MB-231 significantly with respect to DMSO controls, but not in BTF549 [44].
Association: NANOG with Oxaliplatin
Validation Status : Indirect
Evidence: Differential Expression of TF mRNA and Differential TF Protein Concentration
LLR: 5.46
High Scoring Analyses : eQTM only
Observation: Ex vivo models derived from human colorectal liver metastases were treated
with oxaliplatin, 5-flurouracil, and curcumin. Compared to DMSO controls, at 72 hours of
treatment, the triplicate treatment significantly downregulated expression of NANOG [116].
NANOG protein concentration was also shown to be decreased in colorectal cancer stem
cells (CRSCs) when treated with thiostrepton, which acts synergistically with oxaliplatin
in killing CRSCs [117]. Additionally, research has shown that NANOG amplifies STAT3
activation, a regulator shown to be associated with oxaliplatin cellular response [118, 109].
Finally, the Notch signaling pathway, which targets NANOG [123], was shown to be an
important mediator of CRSC self-renewal and proliferation (http://ecommons.luc.edu/
luc_diss/87).
Association: ZNF274 with Ara-C
Validation Status : Indirect
Evidence: Differential Expression of TF mRNA
LLR: 5.00
High Scoring Analyses : eQTL+M, eQTL
Observation: While no literature evidence was found that corroborates this finding, evidence
does exist for the association between gemcitabine, which, like Ara-C, is a deoxycytidine
analog. The link between gemcitabine and ZNF274 was reported by eQTL+M analysis with
an LLR of 3.11. A gene expression profile of gemcitabine treatment to breast cancer cells
revealed that gemcitabine upregulates ZNF274 expression [119].
Association: EZH2 with Radiation
Validation Status : Direct
Evidence: TF siRNA, Differential Expression of TF mRNA and Regulatory Information
LLR: 4.83
High Scoring Analyses : eQTL+M, eQTM
Observation: In a study of epigenetic aberration in radioresistant OML1-R cells, researchers
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identified hypermethylation of the FHIT promoter by H3K27me3 and low FHIT expression.
Further analysis revealed EZH2 overexpression in these cells. EZH2 is a known transcrip-
tional silencer via H3K27me3 and so the investigators knocked down EZH2 via shRNA
to assess its impact on FHIT. Knockdown of EZH2 increased FHIT expression, decreased
H3K27me3 in the FHIT promoter by 2-fold, increased H3K4me3 in the FHIT promoter by
2-fold, and reduced FHIT promoter methylation by 10%. An inhibitor of EZH2 H3K27me3,
GSK343, resulted in increased expression of FHIT; combination therapy with the DNA
methyltransferase inhibitor (DNMT) 5-Aza demonstrated the greatest increase of FHIT ex-
pression among all epigenetic silencers [120]. In a study of glioblastoma (GBM) derived
tumorigenic stem-like cells (GSCs), Kim et al. looked at the role that the catalytic subunit
of Polycomb repressive complex 2, EZH2, and the MELK-FOXM1 complex play in radiosen-
sitivity. It was shown that not only are both EZH2 and MELK co-expressed in GBM and
upregulated following radiation treatment, but that MELK mediated EZH2 signaling is
required for GSC resistance to radiation. They further show that this function is evolution-
arily conserved in Caenorhabditis elegans (C. elegans). The researchers further detailed the
mechanisms by which EZH2, MELK, and FOXM1 may be interacting. Luciferase assays in
overexpression and knockout experiments showed increased EZH2 promoter activity in the
presence of MELK; this finding was corroborated by flow cytometry experiments. The con-
clusion of these findings was that MELK transcriptionally regulated EZH2, at least in GBM
spheres. Given the lack of a MELK DNA binding domain, the researchers searched for a
cofactor that MELK teamed with to regulate the expression of EZH2. The paper concluded
that EZH2 is a direct target of the MELK/FOXM1 transcriptional complex [121].
Association: NANOG with Cisplatin.
Validation Status : Direct
Evidence: TF siRNA
LLR: 4.62
High Scoring Analyses : eQTL+M, eQTL
Observation: The role of NANOG in esophageal squamous cell carcinoma (ESCC) was in-
vestigated, particularly its interaction with cisplatin. ESCCs were confirmed to have high
expression of NANOG via RT-PCR. Several other squamous cell lines have been charac-
terized by NANOG expression, which was hypothesized to be the reason for these cell lines
chemosensitivity to cisplatin. When NANOG was silenced via siRNA in two ESCC cell lines,
the growth inhibitory effect of cisplatin was significantly enhanced [122].
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Table 3.7: All 73 (TF, Drug) Associations in the Top 7 associations for each drug (LLR >3).
D.E indicates Differential Expression of mRNA and D.C. indicates Differential Concentration
of Protein. The subject/object of each experiment is presumed to be the TF unless otherwise
stated.
# TF
Evidence
LLR
eQTL
Code Type L+M M L
1 WRNIP1 6.68 X X
2 NANOG 4.51 X X
3 RCOR1 Indirect Reg by Drug Target 4.23 X
4 FOSL2 3.99 X X
5 FOXA1 3.89 X X
6 TCF7L2 3.77 X X
7 SPI1 3.74 X X
(a) 6-MP
# TF
Evidence
LLR
eQTL
Code Type L+M M L
8 SMARCC1 7.26 X X
9 WRNIP1 7.20 X X
10 NANOG Indirect 6.81 X X
11 ARID3A 6.24 X X
(b) 6-TG
# TF
Evidence
LLR
eQTL
Code Type L+M M L
12 ZNF274 Indirect D.E., 5.00 X X
13 RAD21 Direct siRNA and Cancer Remission 3.59 X
14 TRIM28 Indirect D.P. (Gemcitabine) 3.44 X X
15 ZEB1 Direct Knockdown 3.31 X X
16 TCF12 Indirect D.E. 3.20 X X
17 UBTF 3.03 X
(c) Ara-C
# TF
Evidence
LLR
eQTL
Code Type L+M M L
18 EZH2 Direct Kinase siRNA and miRNA
siRNA and Overexpression
3.62 X X
(d) Arsenic
# TF
Evidence
LLR
eQTL
Code Type L+M M L
19 SP1 Direct ChIP and O.E. 3.85 X X
(e) Carboplatin
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Table 3.7: continued ...
# TF
Evidence
LLR
eQTL
Code Type L+M M L
20 NANOG Direct siRNA 4.62 X X
21 RELA Direct Reporter Assay and siRNA 3.88 X X
22 SMARCC1 Direct Indirect shRNA and Homolog
deletion
3.53 X X
23 RUNX3 Direct siRNA and D.E. 3.51 X X
24 WRNIP1 Indirect Cooperators siRNA 3.49 X X
25 NR3C1 Indirect D.E. 3.10 X X
26 CEBPD Direct Transfection and D.E./D.C. 3.07 X
(f) Cisplatin
# TF
Evidence
LLR
eQTL
Code Type L+M M L
27 BATF Direct siRNA 5.57 X
(g) Docetaxel
# TF
Evidence
LLR
eQTL
Code Type L+M M L
28 HNF4G Direct siRNA 5.48 X X
29 HMGN3 Direct siRNA 3.55 X X
30 TCF7L2 Indirect Pathway Evidence and D.C. 3.50 X X
(h) Doxorubicin
# TF
Evidence
LLR
eQTL
Code Type L+M M L
31 HNF4G Direct siRNA 5.48 X X
32 HMGN3 Direct siRNA (Doxorubicin) 3.55 X X
33 TCF7L2 3.50 X X
34 TAL1 Direct TF Overexpression 3.21 X X
(i) Epirubicin
# TF
Evidence
LLR
eQTL
Code Type L+M M L
35 ZNF143 Some D.E. and TF siRNA (Cisplatin) 3.37 X X
36 USF1 Some D.E. Drug Target and Regulatory Info 3.24 X
37 ZNF274 Indirect D.E. 3.11 X X
38 ARID3A 3.06 X X
39 MAZ 3.03 X X
(j) Gemcitabine
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Table 3.7: continued ...
# TF
Evidence
LLR
eQTL
Code Type L+M M L
40 PRDM1 Direct Reg. Drug Target and D.E. 3.96 X X
(k) Hypoxia
# TF
Evidence
LLR
eQTL
Code Type L+M M L
41 MEF2C Some Reg. Partner of D.E. Drug Target 7.17 X X X
42 NFIC Indirect D.E. 7.08 X X
43 CTCFL 6.90 X X
44 CCNT2 Indirect D.E. 5.67 X X
45 UBTF Indirect D.E. 4.90 X X
46 CBX3 4.37 X X
47 BCLAF1 Indirect D.C. 4.31 X X
(l) NAPQI
# TF
Evidence
LLR
eQTL
Code Type L+M M L
48 STAT3 Direct siRNA and D.C. 6.95 X X
49 NANOG Indirect D.E. and D.C. 5.46 X X
50 TRIM28 Indirect D.P and D.C. 3.58 X X
51 FOSL1 Indirect D.E. and Network Analysis 3.47 X X
52 ZEB1 Indirect Reg. Drug Regulator 3.26 X X
53 ATF1 3.10 X X
54 PPARGC1A Direct TF siRNA 3.05 X X
(m) Oxaliplatin
# TF
Evidence
LLR
eQTL
Code Type L+M M L
55 CTBP2 4.44 X X
56 GATA1 Indirect D.C. and Genomic Alteration 4.81 X X
57 E2F1 Direct D.C. and O.E. 3.58 X X
(n) Paclitaxel
# TF
Evidence
LLR
eQTL
Code Type L+M M L
58 EZH2 Direct siRNA, D.E., and Reg. Info 4.83 X X
59 ESR1 Direct TF Activation and D.E. 4.36 X X
60 PML1 Direct Fluorescence, siRNa, O.E., and N Blot 3.19 X
61 HDAC2 Direct D.C. and siRNA 3.02 X X
(o) Radiation
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Table 3.7: continued ...
# TF
Evidence
LLR
eQTL
Code Type L+M M L
62 GATA1 Direct D.B. and siRNA 5.78 X X
63 STAT2 Direct Fluorescence, siRNa, and W Blot 3.20 X
64 PHF8 Direct O.E. and siRNA 3.08 X
(p) Rapamycin
# TF
Evidence
LLR
eQTL
Code Type L+M M L
65 REST Indirect Reg. Drug Target 4.14 X X
66 NANOG Indirect Reg by Drug Target 3.60 X X
(q) Triciribine
# TF
Evidence
LLR
eQTL
Code Type L+M M L
67 FOXM1 Direct siRNA and D.C. 7.40 X X X
68 RELA Direct siRNA and D.E. 6.52 X X
69 USF1 4.69 X X
70 EBF1 Some 4.49 X X
71 ELF1 Direct siRNA 4.46 X X
72 RUNX3 4.35 X X
73 SMARCC2 4.23 X X
(r) Temozolomide
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Table 3.8: Both tables show experimentally tested (TF, Drug) pairs, selected based on their
high LLR scores, and with trained parameter values either suggesting an effect of the TF
on drug (A) or no effect (B). For each predicted pair, shown is the LLR from the eQTL+M
analysis and whether there was support (marked as x) from eQTL, eQTM, and eQTL+M
analyses. The Validated column and grey shading shows whether the experimental test found
a significant effect on cytotoxicity upon knockdown of TF. Table (B) reveals experimental
validation of only 1 of 8 tested pairs, consistent with our expectation that these pairs should
prove false despite a high LLR, based on parameter values.
Drug TF LLR eQTL eQTM eQTL+M Validated
Epirubicin TCF7L2 8.70 x x x No
Temozolomide FOXM1 14.81 x x x No
6-MP WRNIP1 13.03 x x No
Temozolomide SMARCC2 8.45 x x No
Rapamycin GATA1 10.00 x x Yes
Temozolomide ELF1 8.53 x x Yes
6-MP RCOR1 8.46 x No
6-MP PAX5 6.13 x No
Ara-C UBTF 6.06 x No
Gemcitabine USF1 6.48 x No
Radiation PML 6.37 x No
Ara-C RAD21 7.17 x Yes
Cisplatin CEBPD 6.14 x Yes
Docetaxel BATF 11.14 x Yes
Rapamycin STAT2 6.41 x Yes
Rapamycin PHF8 6.16 x Yes
Temozolomide ZNF263 5.55 x No
(a) Experimentally tested (TF, Drug) pairs in the predicted group, organized by support
from eQTL, eQTM, and eQTL+M analyses.
Drug TF LLR eQTL eQTM eQTL+M Validated
6-MP EZH2 19.98 x x x Yes
6-TG EZH2 23.88 x x x No
6-TG FOXP2 11.30 x x x No
Carboplatin TBL1XR1 9.27 x x x No
Paclitaxel CHD1 8.21 x x x No
6-MP FOXP2 6.44 x No
Oxaliplatin NR3C1 6.64 x No
Cisplatin EZH2 8.87 x x No
(b) Experimentally tested (TF, Drug) pairs in negative control group of associations,
where parameter values suggest lack of evidence for TF association, despite a high LLR
score.
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TOP 73 (TF, DRUG) ASSOCIATIONS BY DRUG
Here, we list and discuss the top (TF, Drug) associations predicted by eQTL+M with an
LLR≥ 3, decomposed by treatment, and ranked by LLR. For each treatment, only up to
seven TFs were examined (see Table 3.7). In parenthesis is the fraction of pairs validated
for each drug, where validation is either direct (knockdown or overexpression) or indirect
(differential expression, differential binding, etc). Observations are also provided for pairs
where we observed some evidence, but not enough to be considered either direct or indirect
validation.
For each drug, we attempted to validate in literature (also leveraging experimental data
from our own analyses on a portion of association) the top 7 associations with an LLR> 3,
resulting in 73 (TF, Drug) associations (see Table 3.7). For those with some, indirect, or
direct evidence of association, we summarize the evidence alongside citations to each of the
referred papers in Appendix A.
3.3.3 EXPERIMENTAL VALIDATION
Certain associations we wanted to test ourselves in the laboratory. We sought to exper-
imentally verify whether TFs associated with drug response variation (by pGENMi) could
be linked in vivo to significant changes in drug-induced cytotoxicity.
We selected predicted (TF, Drug) pairs that reflect a diversity of regulatory support, shown
in Table 3.8. For instance, we selected 10 of the 11 (TF, Drug) pairs identified uniquely by
eQTL+M analysis (we omitted GTF2F1), and two of the three (TF, Drug) pairs predicted
by all three analyses: eQTL+M, eQTL, and eQTM. Additionally, we selected the top four
pairs by LLR in the eQTL+M analysis, that were also supported by eQTM-only analysis.
We also included a high-scoring association from eQTM-only analysis that scored poorly in
the eQTL+M analysis (i.e., LLR< 3).
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Figure 3.3: All 25 experimentally tested (TF, Drug) dosage-response curves. Red outlines
indicate significant shifts in cytotoxicity between siRNA negative and siRNA TF conditions.
Curves with a grey background are eQTL+M predictions, while those with a black back-
ground are negative controls. We confirmed 7 out of 17 predictions and only 1 out of eight
negative controls.
We did not experimentally pursue eQTL-only predictions, as such validations were re-
ported in our previous work [44] and our focus here was primarily on the eQTL+M mode.
All 17 of the these (TF, Drug) pairs were found by pGENMi using learnt parameters consis-
tent with our expectation, i.e., where presence of regulatory evidence relating a TF to a gene
makes the gene more likely to be associated with the drug (parameters wi > 0, for i 6= 0).
For some (TF, Drug) pairs, the maximum likelihood estimation assigned negative values to
both of the wi parameters, while yielding a high LLR score, marking a departure from the
null model. However, such negative weights indicate that the absence of regulatory evidence
relating the TF to the gene is a better marker for linking genes to phenotype, meaning that
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the TF is unlikely to be a regulator of the phenotype. We included eight such (TF, Drug)
associations as a negative control group, pushing the total number of experimental pairs to
25. We expected these eight predictions to prove false, since pGENMi considered them as
statistically interesting but in a manner inconsistent with its mechanistic underpinnings.
Though we largely utilized lymphoblastoid cell lines data for our association analysis,
we performed siRNA knockdown experiments in several different cell lines to demonstrate
the generalizability of our results beyond LCLs. Based on clinical relevance, the human
triple negative breast cancer MDA-MB-231 cells were chosen to test anthracyclines, tax-
anes, platinums, gemcitabine, radiation, and rapamycin cytotoxicity, because these drugs
are typically administered as first-line therapy for triple negative breast cancer. We used a
human leukemia Jurkat cell line to test 6-MP, 6-TG, and Ara-C since these drugs are used
to treat leukemia. Temozolomide is the first-line therapy for glioblastoma multiforme; we
therefore used human glioma U251 cells to validate the TFs associated with Temozolomide
response. The siRNA knockdowns were performed for the 25 (TF, Drug) pairs shown in
Table 3.8 for the eQTL+M predicted and negative control associations respectively. Cyto-
toxicity graphs of all knockdowns are shown in Figures 3.3, while those separated by drug
are shown in Appendix B. Overall, 7 of 17 (∼41%) of predicted associations (Table 3.8A),
were validated in this way, compared to 1 of 8 (∼ 12%) of negative control associations
(Table 3.8B). Interestingly, this overall precision of 41% in our own validations is similar to
the corresponding precision observed across all drugs (Table 3.5, Direct evidence). Addi-
tionally, the precision on the 10 unique eQTL+M predicted associations was 50% (5 of 10),
compared to 0% (0 of 2) of negative control associations unique to eQTL+M mode; this
indicates pGENMi is able to combine multiple lines of regulatory evidence to make novel
regulatory predictions that may be unreported when considering each line of evidence in
isolation. With respect to the (TF, Drug) pair predicted uniquely from eQTM analysis (and
not predicted eQTL- or eQTLM-only), we failed to validate it in our experiments. Nev-
ertheless, we believe that our experimental validation demonstrates the utility of pGENMi
predictions overall and especially when combining multiple sources of regulatory information
to learn novel associations.
3.3.4 PGENMI PRODUCES MORE DISTINCT ASSOCIATIONS THAN SIMPLE
METHODS
The pGENMi eQTL+M analysis, with results restricted to those with an LLR≥ 3, pro-
duced 90 (TF, Drug) associations. As no such algorithm other than GENMi [44] exists for
associating TF cis-regulatory influence with drug response, and even GENMi is incapable of
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handling both genotype and methylation information simultaneously, there were no obvious
reported baseline methods to which we could compare pGENMi so we constructed two sim-
ple baselines. In the first, a TF is considered associated with a drug if the TFs expression
correlates significantly with cytotoxicity, an approach recently used for identifying genes as-
sociated with drug response [36]. This baseline approach reported 121 associations at FDR
0.1 (chosen so that the number of reported associations is similar to that of pGENMi). How-
ever, these associations were mostly distinct from those reported by pGENMi; between these
121 associations and the 90 associations reported by pGENMi, only five associations (hy-
pergeometric p-value = 0.19) were shared. Similar observations of complementarity between
results were made when using other thresholds of significance.
In a second baseline method, a TF is associated with a drug if the top drug response
genes are enriched for strong nearby ChIP peaks of that TF. Performing a hypergeometric
test between the top 500 target genes of a TF, based on the maximum ChIP score in the
50 Kb upstream region of each gene, and the top 500 drug response genes from a TWAS
analysis yielded 126 (TF, Drug) pairs at an FDR of 0.1 (correction performed per drug).
Similar to the first baseline, only two were shared with the pGENMi approach. The results
of both baseline analyses demonstrate that pGENMi reveals novel insights into regulatory
mechanisms of drug response, based on cis-regulatory analysis, that may not be obtained
from the current approach of expression-phenotype correlations or from analyses that identify
gene targets purely on the basis of the distribution of strong ChIP peaks.
We also investigated the extent to which sub-significant results in the baseline were en-
riched with pGENMi. Relaxing the 0.10 FDR threshold to 0.25 produced 253 associations
rather than 121, though the overlap with the 90 pGENMi associations only increased to 6
(hypergeometric p-value = 0.63). We further diluted the statistical reliability of the TWAS
associations by reporting associations based on uncorrected p-values ≤ 0.05. Of the 384 as-
sociations matching this criterion (among the 3552 test), the overlap with pGENMi yielded
only 10 associations (hypergeometric p-value = 0.51).
3.3.5 TOP PGENMI ASSOCIATIONS OVERLAP WITH GENMI BUT MOST ARE
NOVEL
pGENMi formalizes the statistical procedure of GENMi [44] and extends it to handle
multiple regulatory evidences. As such, it is fair to ask to what extent these two related
procedures produce similar results. We therefore ran GENMi to test the enrichment between
genes ranked by their TWAS p-value pertaining to a given drug and genes with either cis-
eQTL or cis-eQTM evidence for that TF.
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Table 3.9: Concordance between pGENMi and GENMi eQTL+M and eQTL-only models.
Intersection/Union (Jaccard Coefficient) of top 90 (TF, Drug) associations from various
pairs of analyses that differ in model (pGENMi versus GENMi) or data (eQTL+M versus
eQTL-only).
Top 90 (TF, Drug) pairs
pGENMi GENMi
eQTL+M eQTL-only eQTL+M eQTL-only
pGENMi
eQTL+M
eQTL-only 48/132 (36%)
GENMi
eQTL+M 24/156 (15%) 24/156 (15%)
eQTL-only 22/158 (14%) 29/151 (19%) 44/136(32%)
Comparing the top 90 (TF, Drug) pairs by p-value produced by GENMi and the top 90
(TF, Drug) pairs produced by pGENMi using both eQTL and eQTM evidence reveals an
overlap of 24 (TF, Drug) pairs (hypergeometric test p-value 1.1 E-17), corresponding to a
Jaccard coefficient of 15.4%, shown in Table 3.9. Of these 24 pairs, ten showed directly val-
idation either through our experiments or in the literature. While a strong overlap between
the top associations from these two related methods is expected, it also underscores that
pGENMi finds several associations 66 of the top 90 that were not reported by GENMi
using the same rank threshold (47 were ranked below 300, out of 3000, by GENMi). This
complementarity arises due to the difference of models used in the two analyses, since the
same data were utilized.
Comparison of GENMi and pGENMi results (top 90 pairs) obtained from eQTL-only or
eQTL+M data, in all four combinations, revealed an overlap of 22-29 pairs (Table 3.9). The
commonalities were much greater when results from eQTL+M analysis were compared to
those from eQTL-only analysis, using the same method, than when pGENMi and GENMi
were compared using the same data (Table 3.9). For example, the top 90 predictions by
pGENMi with eQTL+eQTM data and by pGENMi with eQTL data share 48 associations,
while top 90 predictions by pGENMi with eQTL data and by GENMi with eQTL data share
only 29 associations. Thus, roughly speaking, a greater difference in predicted associations
arises in changing the model (from GENMi to pGENMi) than in adding eQTM data to
pGENMi analysis (from pGENMi eQTL-only to pGENMi eQTL+M).
In the absence of a reliable benchmark of true associations and given the impracticality
of extensive literature-based assessment of each of the analyses reported in Table 3.9, it is
difficult to argue empirically if one analysis is more accurate than another. However, it is
fair to conclude that the majority of the top associations reported by pGENMi are exclusive
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Figure 3.4: Distribution of GM12878 ChIP pGENMi eQTL-only Log-Likelihood Ratios
(LLR) for tested (TF, drug) pairs for which the corresponding LLR with Composite ChIP
data is < 1 (blue) or ≥ 1(green) respectively.
to it in comparison with results from GENMi, regardless of the mode of analysis.
3.3.6 CELL LINE SPECIFIC CHIP DATA AND COMPOSITE CHIP DATA ALTER
RESULTS
As the genotype, methylation, gene expression, and cytotoxicity data all were derived
from the same panel of cell lines, we inquired whether restricting ChIP peaks to those from
lymphoblastoid cell lines produced different results than when using a union of clustered
peaks across cell lines (composite ChIP data), which was the strategy used for the analyses
above. To test this, we ran pGENMi using eQTL data co-incident with GM12878 ChIP
peaks from ENCODE and compared the results to the eQTL-only analysis using composite
ChIP peaks.
Among the 37 GM12878 specific TFs and 24 drugs tested, we tested 888 (TF, Drug)
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associations, of which 90 pairs exhibited an LLR ≥ 1.74. At the same threshold, and when
testing the same candidate pairs, the composite ChIP analysis produced 29 associations,
with only three associations (ELF1, 6-MP), (MAX, 6-MP), and (NFIC, 6-TG) being
common with the analysis based on GM12878 peaks. We noted that pairs with LLR ≥ 1
in composite ChIP analysis had a greater tendency (compared with those with LLR < 1)
to be in the significant list of the GM12878 ChIP analysis (t-test p-value 3.05E-04, see
Figure 3.4) Overall, our conclusion from this comparison is that the top associations reported
by pGENMi depend significantly on the source of the ChIP data use to infer regulatory
evidence, which is expected. Our use of composite (multiple cell line) ChIP data in the
results reported in this work was motivated by our search for associations that generalize
beyond lymphoblastoid cell lines, to other cancer cell lines where many of the associations
validated in the literature as well in this study have been demonstrated.
Table 3.10: The decomposition of TFs associated with drugs among the top 90 (TF, Drug)
pairs for the GM12878 eQTL-only pGENMi analysis
Drug # TFs associated in top 90 (TF, Drug) pairs
Rapamycin 1
Triciribine 1
Hypoxia 2
NAPQI 2
Gemcitabine 2
Fludarabine 4
Radiation 5
Arsenic 6
6-MP 14
Doxorubicin 16
Epirubicin 18
6-TG 19
It is notable that the GM12878 specific analyses produced a substantially greater number
of associations above the reporting threshold. One reason for this may lie in the difference
between the GM12878 and Composite ChIP analyses in terms of the number of target genes
(those with regulatory evidence) for each TF. For instance, the median number of target
genes with cis-eQTL evidence for a TFs influence is 58 per TF and 151 per TF for Composite
and GM12878 ChIP data respectively; the mean number of target genes per TF based on
either cis-eQTL or cis-eQTM (eQTL+M) evidence improves to 102 for the composite ChIP
data and 155 for the GM12878 data.
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Table 3.11: The decomposition of drugs associated with TFs among the top 90 (TF, Drug)
pairs for the GM12878 eQTL-only pGENMi analysis
Drug # TFs associated in top
90 (TF, Drug) pairs
BHLHE40 1
EGR1 1
BATF 1
RELA 1
USF2 1
SPI1 1
BCL11A 1
USF1 1
NFYB 2
EBF1 2
PAX5 2
ZEB1 2
POU2F2 2
NFATC1 2
IRF4 2
MEF2A 2
BCL3 2
ATF2 2
TCF3 2
RUNX3 3
TCF12 3
SRF 3
MTA3 3
ZNF143 4
MAX 4
NFIC 4
MXI1 5
FOXM1 5
YY1 5
ELF1 5
SP1 5
SIN3A 5
PML 6
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Table 3.12: The number of TWAS genes (of 16183) at varying p-value thresholds and the
number of pGENMi eQTL+M associations for those drugs at LLR ≥ 3
Drug
# TWAS gene with p-value ≤ pGENMi
eQTL+M as-
sociations at
LLR ≥ 3
0.005 0.0005
6-MP 956 397 15
NAPQI 103 12 13
Temozolomide 324 133 10
Cisplatin 862 265 7
Oxaliplatin 562 227 7
Cytarabine 854 376 6
Gemcitabine 298 68 5
6-TG 882 377 4
Epirubicin 313 64 4
Radiation 181 27 4
Doxorubicin 318 74 3
Paclitaxel 176 34 3
Rapamycin 113 21 3
Triciribine 257 77 2
Arsenic 147 22 1
Carboplatin 1339 489 1
Docetaxel 138 27 1
Hypoxia 82 6 1
Cladribine 61 6 0
Everolimus 79 17 0
Fludarabine 88 12 0
Metformin 368 57 0
MPA 112 9 0
Methotrexate 56 7 0
The detection discrepancy between the two analyses that leads to fewer targets in the
Composite ChIP analysis may be due, in part, to the clustering across cell lines which
dilutes LCL specific ChIP signals and high occupancy target (HOT) region removal. It does
not seem exceptional that LCL derived eQTLs would be more enriched in LCL specific ChIP
peaks. Another reason for the GM12878 specific analyses exhibiting may be the asymmetric
distribution of TFs associated with drugs in the analysis using GM12878 ChIP data.
As shown in Table 3.10, the 4 drugs 6-MP, Doxorubicin, Epirubicin, 6-TG account for 67
of the 90 (TF, Drug) associations observed at a LLR ≥ 1.74. Two of these drugs 6-MP
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and 6-TG also had among the largest number of TWAS genes, which together with the
larger numbers of target genes designated with GM12878 ChIP data may have resulted in
the inflated numbers of TF associations. The enrichment of associations for these drugs may
also indicate a greater sensitivity to them in this cell line. Table 3.11 shows the distribution
of associated drugs for each TF at the LLR ≥ 1.74 threshold.
We maintain that the composite ChIP analysis offers a more balanced and generalizable
view of the regulatory landscape for a TF and thus is more robust to validation in other cell
lines and tissues. We leave more in depth analysis of the utility of cell line specific ChIP
data for future research.
3.3.7 POTENTIAL FACTORS LEADING TO FALSE POSITIVES IN PGENMI
Validation rates of pGENMi predictions, based on literature search or our own experi-
ments, were around 40% overall, which is far from perfect, and highly variable across drugs.
One of the potential reasons for false positives is the great variation among drugs in terms of
the number of significant TWAS genes, i.e., genes with significant correlation between their
expression and cytotoxicity.
Table 3.13: The median and mean number of TWAS genes (of 16183) at varying p-value
thresholds and the median and mean number of pGENMi eQTL+M associations at LLR
≥ 3 for the Top 5 and Bottom 19 drugs by the # of pGENMi eQTL+M associations at ≥ 3
Statistics
# TWAS gene with p-value ≤ pGENMi
eQTL+M as-
sociations at
LLR ≥ 3
0.005 0.0005
Top 5 Drugs
Median 562 227 10
Mean 561.4 206.8 10.4
Bottom 19 Drugs
Median 176 27 1
Mean 308.5 93.2 2
We tabulated the number of significant TWAS genes alongside the number of pGENMi
eQTL+M associations (LLR ≥ 3) for each drug in Table 3.12. The five drugs with most
reported associations (6-MP, NAPQI, Temozolomide, Cisplatin, Ara-C) - about 10 TFs
on average - show far more TWAS genes (median of 227), compared to the remaining 19
drugs, which typically yield about 1 TF association (median) and have only 27 TWAS genes
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(median); see Table 3.13. This raises the possibility that pGENMi makes false positive pre-
dictions in cases when there are significantly more phenotype-associated genes. Pursuing
this further, we noted that for the top five drugs by number of associations, our literature-
based validation (Table 3.4) found direct evidence for only 10 of 35 (29%) predicted TF
associations, while for the remaining 19 drugs we were able to find similar direct evidence
for 20 of 38 (53%) TF associations predicted by pGENMi, a statistically significant dif-
ference (hypergeometric test p-value 0.032). Similar observations were made on our own
experimental validations (Table 3.8A), though small sample sizes prevent statistical claims.
For instance, two of the above-mentioned top 5 drugs had 3 or more TFs tested by us (6-MP
and Temozolomide), and both yielded low validation rates (0/3 and 1/4 respectively), while
the drug Rapamycin, for which only 3 predictions were made and all three were tested by
us, yielded a success rate of 3/3. In light of the above observations, we believe that the
accuracy of pGENMi predictions may suffer when a phenotype variation is correlated with a
large number of genes expression levels, and future work should attempt to rectify this issue
if possible.
Another possible factor leading to false positives is that extensive co-binding of a pair
of TFs leads to the method mistaking the co-bound TF for the true regulator. We have
tried to address this potential source of false positives by removing HOT regions where most
co-binding is observed from our analysis. Many TF pairs are known to exhibit significant
co-binding even after HOT region removal, as demonstrated by the ENCODE project, and
thus it is possible that some of the false positives arise from co-binding. In such cases, if the
true TF is among those tested by us (i.e., has ENCODE ChIP data), then we would expect
that it should also score highly in the pGENMi analysis. For example, in our experimental
validation, we predicted that ELF1 and ZNF263 were both associated with temozolomide,
but only succeeded in validating ELF1 through cytotoxicity assays, while ZNF263 knockdown
did not show significant change in response. ENCODE reports that these two TFs co-bind
across the whole genome in K562 cells [123], so it is possible that the predicted ZNF263
association was a false positive because of the true ELF1 association and the ELF1-ZNF263
co-binding.
Finally, with regards to the experimental validation, some (TF, Drug) pairs didnt validate
in vivo because of the assay design; (FOXM1, Temozolomide) and (PML, Radiation) were
validated directly in tissues according to the literature, but both failed to validate in vivo
in cell lines. Furthermore, we validated (FOXM1, Temozolomide) in recurrent glioblastoma
multiforme (GBM) tumor but failed to validate in U251 which is derived from completely
different tissue than GBM. The same holds for (PML, Radiation), which was validated most
strongly in mouse embryonic fibroblasts (MEFs), and which failed in a triple negative breast
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cancer cell line (MDA-MB-231) completely unlike MEFs. Because (TF, Drug) pairs may
be context (cell-line) specific, failure to validate in certain cell lines cannot be interpreted
necessarily as a rejection of the relationship altogether, as the two examples above show.
3.3.8 PGENMI COMPARISON TO GPA
The Genomic Pleiotropy with Annotation (GPA) [88] algorithm is similar in spirit to
pGENMi. GPA uses latent variables for SNPs and integrates the GWAS p-value of a SNP
with annotations of that SNP; pGENMi in contrast uses latent variables for genes and
integrates the TWAS p-value a gene with annotations of that gene based on eQTL, eQTM
and TF ChIP peak evidence. The commonality between the two models, is thus at a higher
conceptual level rather than at a practical level that might warrant empirical comparisons.
Even at the technical level there is a key difference in that GPA models the joint likelihood
of the annotations and GWAS p-value of SNPs, whereas we only use regulatory evidence to
maximize the likelihood of TWAS data.
3.3.9 DATABASE OF (TF, DRUG) ASSOCIATIONS
We made available as an online resource all (TF, Drug) associations validated using siRNA
or overexpression experiments in this study as well as those found to be similarly validated
in our survey of the literature, the GENMi study [44], and a related work that performs the
same experimental validations [124]. This resource is available at veda.cs.uiuc.edu/pgenmi.
We believe this to be the first such catalog of experimentally validated (TF, Drug) pairs.
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CHAPTER 4: CONCLUSION
In this work, we have demonstrated the ability to identify TFs which work through inter-
mediary target genes to implement the cellular response to drugs, via a statistical enrichment
model (GENMi). We also extended such a statistical model into a more flexible probabilistic
formulation that can successfully associate TFs with drug response via multiple regulatory
modalities, in a manner that generates novel associations that would not have otherwise
been discernable from either analysis individually. Both of these methods provide principled
ways to discover the regulatory mechanisms underlying phenotypic variation among indi-
viduals. We demonstrated a high rate of success in validating our associations through a
comprehensive literature survey and in vivo experimental validation and have collated the
validations from our and other studies into a (TF, Drug) association database.
While we view the pGENMi model as a major improvement over our previous proof-of-
principle approach [44], it is similar to various existing models for data integration. pGENMi
somewhat resembles the GPA model [88] except that GPA, by modeling SNPs instead of
genes as latent variables, applies primarily to GWAS data analysis. Furthermore, we use
an empirical Bayesian approach similarly used to prioritize SNPs using annotations [91]
and Battle et. als latent regulatory variant model (LRVM) [92]. The pGENMi model, al-
though unique in the way that it combines cis-regulatory information with inter-individual
co-variation in gene expression and drug response, is not wholly unique in identifying TFs
relevant to phenotype. There exist categories of algorithms dedicated to implicating tran-
scriptional mechanisms or regulatory networks specific to certain phenotypes [125] [126]
[127]. The main distinction of the pGENMi approach is that it uses data on population-
level variations in genotype, epigenotype, gene expression and phenotype to uncover those
mechanisms. Its findings are thus expected to be more relevant to what underlies individ-
ual differences in phenotype, as opposed to a more general catalog that includes TFs that
may be relevant to the phenotype but not so much to its individual-level variations. On a
relatively minor note, the above methods for reconstructing context-specific transcriptional
regulatory networks require data on discrete cellular conditions (disease vs non-disease state
for instance) and are thus distinct from pGENMi which focuses on inter-individual contin-
uous variation in cellular phenotype. TF associations with drugs can also be inferred from
general studies that prioritize genes related to drug response based on prior functional net-
works [124] [128] [129] or based on observed or imputed gene expression alone [130] [36] [33]
[131]. These approaches are not focused on identifying regulators of phenotype based on
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cis-regulatory evidence.
Validation rates of pGENMi predictions, based on literature search or our own experi-
ments, were around 40% overall, which is far from perfect, and highly variable across drugs.
Exploring possible reasons for false positives, we noted great disparity among drugs in terms
of the number of significant TWAS genes (i.e., whose expression is associated with pheno-
typic variation), and that pGENMi predicts more associations, with lower validation rates,
for drugs with more TWAS genes (Table 3.12-3.13). In some cases, extensive co-binding of a
pair of TFs may also have led to false positives, with peaks of the true regulator mistakenly
providing evidence in favor of the co-binding TFs influence on several TWAS genes. With
regards to experimental validation, some (TF, Drug) pairs didnt validate in vivo because of
the assay design; (FOXM1, Temozolomide) and (PML, Radiation) were validated directly in
tissues according to the literature, but both failed to validate in vivo in cell lines. Because
(TF, Drug) pairs may be context (cell-line) specific, failure to validate in certain cell lines
cannot be interpreted necessarily as a rejection of the relationship altogether.
pGENMi can be improved in a number of ways; for instance, our model makes the im-
plicit assumption that a latent variable zg representing a genes involvement in mediating
the TFs influence on phenotype is independent across genes; however, co-regulated gene sets
break this assumption and it would be more reflective of the underlying biology to model
a network of latent variables zg instead of treating each gene independently. Our choice
of modeling the p-values of gene expression-phenotype correlation as arising from a Beta
distribution avoids the use of arbitrary thresholds on the strength of this relationship, but
we believe there may be less restrictive ways to explicitly model phenotype-expression re-
lationships. Although we integrated more types of data in this work than typical studies
that directly relate gene expression to drug response data [36] [130]), the model allows fur-
ther extensions. For instance, incorporating the impact of various histone modifications and
other epigenetic marks will be an interesting endeavor if such variants are profiled in the cell
line panel. Additionally, it may be wise to consider in vivo assays to validate the mediators
of drug response, in addition to the TFs themselves, in the future. Despite these various
areas of improvement, the pGENMi methodology was successful in integrating both genetic
and epigenetic variation to elucidate the regulatory association between a TF and drug, as
evidenced by our 50% precision in validating those predictions only eQTL+M reported. We
hope this methodology can serve as a blueprint for future endeavors that aim to elucidate
the regulatory basis of disease etiology using multiple molecular profiles of variation.
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The pGENMi framework need not be restricted to the analysis of the variation of drug
response. It may be easily adapted for use in other situations where one seeks to link a
phenotype to a set of gene properties, e.g., regulation by a TF, membership in a pathway,
involvement in a biological process, etc., while using gene expression as an intermediate
variable. The relationship between gene expression and phenotype may be quantified by
differential expression p-values if, for instance, the phenotype is binary as in case versus
control studies or in before versus after treatment studies.
From a computational modeling standpoint, one might wonder about the utility of choos-
ing this pGENMi probabilistic methodology; after all, there are many different categories
of machine learning algorithms from which one might choose. We concede that the point
of this endeavor was not to survey the relevant and applicable methods and to identify the
best such one for this task; the task is novel. Therefore, our focus was to identify a model
that could answer the biological questions we set forth. The probabilistic methodology we
choose is natural in the sense that (a) it is a probabilistic extension of the intuitive statis-
tical methodology GENMi and (b) similar methods have been published analyzing different
entities such as GWAS data, albeit with slightly different graphical structure. We under-
stand the limitations in using summary data (p-values) rather than relying on the samples
themselves in the analysis. However, the works outlined in this paper are association studies
and, therefore, it is appropriate to use summary statistics, especially when data comes from
disparate sources. In moving forward, it will be instrumental to incorporate a sample level
framework in moving from association analysis to analyses that can make stronger claims.
Regarding the problem as a whole of identifying regulatory mechanisms underlying drug
response variation, there are number of ways in which this work can be extended. Moving
away from treating each target gene independently from other genes to a network-based ap-
proach is one such logical extension; analyzing regulatory and drug response variation in this
context empowers clinical and laboratory scientists, as much of the literature describing drug
response variation is on the level of pathways rather than individual genes. Another avenue
lies in integrating the entire signal transduction pathway, incorporating phosphorylation and
other signaling data in addition to the -omic correlations in this study. This extension would
help filter out spurious correlations at the -omic level while boosting marginally significant
correlations whose relationships are consistent with the underlying signaling. Incorporating
prior biological knowledge into these analyses would help tremendously. Thus far, we have
relied on relations between -omics entities derived from the dataset itself. However, any
single dataset is likely to be biased and incomplete and incorporating both known biological
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associations and de novo associations will likely merge the best of both worlds. Finally,
the drug response models and TF-target models used in this study are simplistic. More
elaborate drug response models and TF-target gene models that incorporate both expres-
sion and ChIP data will obviously go a long way toward improving the general algorithmic
performance. Overall, the work this thesis represents is an entry point into the intersection
of pharmaco- and regulatory genomics and their remains many future work to fully analyze
the relationship between these two genomic domains.
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APPENDIX A: TOP 73 (TF, DRUG) ASSOCIATION VALIDATIONS
This chapter contains the literature research conducted for those TFs whose validation
in Table 3.7 was not mentioned. For each (TF, Drug) association, we report several fields.
The first is the Validation Status field, which indicates whether we consider this association
to be direct validation (exhibited usually by TF knockdown) or indirect (exhibited usually
by TF mRNA differential expression or binding in response to the treatment). The second
field, Evidence, summarizes the evidence we found for the association. The next field,
LLR, contains the pGENMi eQTL+M LLR for the association. The following High Scoring
Analyses field contains the experiments that yielded a significant LLR; for eQTL and eQTM,
the LLR threshold was 1.74. Since we only examine significant eQTL+M pairs in this
analysis, every association should at least have eQTL+M in this field. The last field is
Observation which is a paragraph describing literature evidence we found corroborating the
(TF, Drug) association or at least providing some evidence as to its validity.
As previously said in the pGENMi Chapter, for each drug, we attempted to validate in
literature (with our own results) the top 7 associations with an LLR > 3, resulting in 73
(TF, Drug) associations (see Table 3.7). For those with some, indirect, or direct evidence of
association, we summarize the evidence alongside citations to each of the referred papers in
the following:
6-MP: (1/7)
Association: NANOG with 6-MP
Observation: Though we failed to corroborate this finding in the literature, we have found
NANOG to be associated with at least 4 other drugs. Knockdown of NANOG has been
shown to increase sensitivity in cancer cells to cytotoxic agents like cisplatin [122] and re-
duce malignancy potential [132]. Overexpression of NANOG has also been shown to increase
resistance to docetaxel [133]. Thus, while we failed to corroborate this association, NANOG
appears to be important in cancer and drug resistance more broadly.
Association: RCOR1 with 6-MP
Observation: The nuclear receptor NR4A2 has been shown to be activated by 6-MP in CV1
and HEK293 cells [134]. In microglia cells and astrocytes, NRF4A2 recruited COREST
(RCOR1) in clearing RELA via transcriptional repression [135]. Given that NRFA2 is a
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target of 6-MP and interacts with RCOR1 in transcriptional repression of RELA, it stands
to reason that RCOR1 is associated with 6-MP, albeit indirectly through NRFA2.
Association: TCF7L2 with 6-MP
Observation: TCF7L2 is known to be involved in drug resistance [136]. In investigating
the effect of NR4A3 variant (coding SNP rs12686676) in insulin gene regulation and insulin
secretion in -cells, researchers found a gene-gene interaction between the NR4A3 allele and
a variant of TCF7L2 (SNP rs7903146). The NR4A3 allele is known to increase insulin se-
cretion, while the TCF7L2 allele decreases secretion. Haplotypes with wild type TCF7L2
and variant NRFA3 do not exhibit significant increase or decrease in insulin secretion com-
pared to haplotypes that are wildtype for both genes. However, haplotypes with variant
TCF7L2 and variant NR4A3 show much higher secretion of insulin compared to haplotypes
with wildtype NR4A3 and variant TCF7L2, indicating that the NR4A3 can restore insulin
secretion in comprised systems with variant TCF7L2. It is widely known that the NR4A
subgroup can be activated by 6-MP via the AF-1 domain [137]. Given the interaction be-
tween TCF7L2 and NR4A3 as well as NR4A3s activation by 6-MP, we conclude that there
is some evidence that TCF7L2 is associated with 6-MP, but not enough to warrant indi-
rect or direct validation status. In a separate study examining the effect of azathioprine, a
purine anti-metabolite akin to 6-MP, on carcinogenesis in mice found frameshift mutations
in TCF7L2 and seven other genes involved in carcinogenesis when at least one copy of the
DNA repair protein MSH2 in the mice was absent [138].
6-TG: (0/4)
All four associations uncorroborated
ARA-C: (5/6)
Association: ZNF274 with Ara-C (Stated in pGENMi main text)
Association: RAD21 with Ara-C
Observation: In our study, siRNA knockdown of RAD21 in Jurkat cell lines shifted the
cytotoxicity curve of Cytarabine significantly compared to DMSO controls. Additionally,
somatic mutations in RAD21 have been identified as a key driver in acute myeloid leukemia
(AML) development; treatment of cytarabine and indarubicin has been shown to achieve
remission in patients with cohesin mutations in STAG2, SMC3, and RAD21 [139].
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Association: TRIM28 with Ara-C
Observation: TRIM28 is an ataxia telangiectasia mutated (ATM) substrate activated by
DNA double strand breaks. In exposing multiple myeloma cells with a combination of gem-
citabine (a pyrimidine analog akin to cytarabine) and a purine analog, clofarabine, ATM
kinase substrates such as histone 2AX, TRIM28, and p53 were phosphorylated [140], indicat-
ing that the ATM pathway (including TRIM28) is activated by this combination. Another
study demonstrated that depletion of ATM in HeLa and A549 cells sensitized them to gemc-
itabine therapy further supporting the importance of this pathway in gemcitabine treatment
[141].
Association: ZEB1 with Ara-C
Observation: In a study investigating the role of ZEB1 in differential response to chemother-
apy in mantle cell lymphoma (MCL), the investigators knocked down ZEB1 by introducing
salinomycin to MCL cells; ZEB1 depends on WNT signaling for expression and salnomycin is
a WNT blocker. After ZEB1 knockdown, the researchers noticed increased chemosensitivity
of MCL cells to the cytotoxic effects of doxorubicin, cytarabine and gemcitabine [142].
Association: TCF12 with Ara-C
Observation: In a work detailing the effects of cytarabine on ectoderm and mesoderm devel-
opment in human embryonic stem cells (hESCs), the investigators performed a differential
gene expression assay on hESCs. They demonstrated that cytarabine upregulates TCF12
expression in this cell type [143].
ARSENIC: (1/1)
Association: EZH2 with Arsenic
Observation: An analysis of the involvement of JNK and STAT3 in AKT-mediated phospho-
rylation of EZH2 revealed a critical insight into the role of arsenic in bronchial epithelial cells.
It was shown that treating bronchial epithelial cells (BEAS-2B) with arsenic induces phos-
phorylation of EZH2. This was demonstrated by first transfecting cells with siRNA targeting
JNK1; such cells showed a loss of phosphorylation of STAT3, diminished AKT activity, and
thus a loss of phosphorylation on serine 21 of EZH2. The researchers also illustrated that
arsenic targets the AKT pathway by inducing miRNA-21, a miRNA regulated by STAT3. Si-
lencing this miRNA in transfected arsenic-induced cells diminished phosphorylation of EZH2,
while ectopic overexpression of miRNA-21 resulted in EZH2 phosphorylation [144]. With
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respect to cell cycle arrest generally, EZH2 has also been implicated as a significant player in
SWI/SNF, a family of proteins that consume ATP to remodel nucleosomes, deficient cells;
this was shown via inhibition of EZH2 in SMARCB1 (a member of the SWI/SNF family) de-
ficient rhabdoid cells, which led to alterations of H3K27 trimethylation and cytotoxicity [145]
CARBOPLATIN: (1/1)
Association: SP1 with Carboplatin
Observation: It has been established via chromatin immunoprecipitation (ChIP) assays that,
in tumor copper deficient cells, SP1 regulates SLC31A1 by binding to the SLC31A1 pro-
moter. The SLC31A1 protein is a membrane protein that transports copper into the cell,
and, more importantly, platinum drugs such as cisplatin and carboplatin. Low expressing
individuals of SLC31A1 are typically resistant to the chemotherapy of platinum drugs. It
has been shown that SLC31A1 can be induced in copper deficient environments through
upregulation of SP1, thereby leading to greater chemosensitivity to platinum agents. Such
experiments have already been performed with cisplatin and preliminary studies are encour-
aging for carboplatin therapy [146]. Additionally, a separate study showed that inhibition of
SP1 binding to the promoter of BIRC5 (survivin), an antiapoptotic protein highly expressed
in cancer and linked to drug resistance, decreased expression of BIRC5 [147], implicating
SP1 more broadly in chemotherapy.
CISPLATIN: (7/7)
Association: NANOG with Cisplatin (see Direct Associations)
Association: RELA with Cisplatin
Observation: It was shown in HeLa 57A cells that treatment of cisplatin reduced transcrip-
tional expression of RELA, via luciferase reporter assays. Additionally, further investigation
found that cisplatin treatment downregulated BCL2L1. A separate study by the same group
demonstrated that RELA is required for activation of BCL2L1 through siRNA knockdown
of RELA [148]. Another study examining the interaction of RELA and cisplatin focused
on the differential phosphorylation of the T505 residue of RELA by CHEK1 in response to
cisplatin treatment in mouse embryonic fibroblasts. The researchers found that T505 phos-
phorylation induced a proapoptotic form of RELA that could facilitate cell death through
transcriptional repression of antiapoptotic target genes such as BCL2L1 [149].
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Association: SMARCC1 with Cisplatin
Observation: SMARCC1 is a member of the SWI/SNF family of proteins that remodel nu-
cleosomes. A study of the cytotoxicity of cisplatin in head and neck squamous cell carcinoma
revealed that SMARCA4 and SMARCA1 increase sensitivity to cisplatin, via shRNA knock-
down experiments [150]. Another study showed that the suppression of SWI/SNF factors
(SMARCB1, SMARCC1, SMARCC2, SMARCD1, SMARCD3) via siRNA sensitized cells to
cisplatin at the same level as ARID1A and ARID1B suppression in U2OS cells [71]. Further-
more, in yeast, the YJL175W open reading frame deletion that confers cisplatin resistance
overlaps with SWI3, the yeast ortholog of SMARCC1 [151].
Association: RUNX3 with Cisplatin
Observation: Examining the role of RUNX3 in gastric cancer chemotherapy, siRNA knock-
down of RUNX3 sensitized immortalized stomach mucosal cells (GES-1) and gastric cancer
cells (SGC7901) to cisplatin [152]. Another study in hepatocellular carcinoma (HCC) look-
ing at the role of miR-130a/RUNX3/WNT signaling in cisplatin treatment demonstrated
through siRNA knockdown of miR-130a and RUNX3 that miR-130a inhibits RUNX3 which
activates WNT signaling and results in cellular resistance to cisplatin treatment [153]. Fur-
ther studies have shown differential expression of RUNX3 in cells treated with cisplatin [154]
[155].
Association: WRNIP1 with Cisplatin
Observation: In an investigation of ZRANB3, siRNA knockout in U2OS cells resulted in
dramatic sensitization to camptothecin (CPT) and moderate sensitization to cisplatin. The
study also elucidated cooperativity between ZRNAB3 and WRNIP1 [156]. In a study of
chicken DT40 cells, knockdowns of WRNIP1 did not desensitize the cell to cisplatin, but
moderately to CPT; however, negative cells of RAD18, which interacts with WRNIP1, did
exhibit high sensitivity to both cisplatin and CPT [157].
Association: NR3C1 with Cisplatin
Observation: In OC-k3 mouse hairs cells, researchers showed that cisplatin treatment up-
regulated expression of NR3C1 in vitro [158]. However, in a transcriptomic profile of human
cellular response to cytotoxic agents, NR3C1 was found to be downregulated by cisplatin
treatment [159]. This contradiction may be due to the differing regulatory architectures be-
tween the species, as it is likely cisplatin does not interact directly with NR3C1 Additionally,
NR3C1 is a glucocorticoid receptor (GR) and glucocorticoids (GC) have been shown to be
enhance cytotoxicity [160].
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Association: CEBPD with Cisplatin
Observation: In analysis of human urothelial carcinoma cell line NTUB1, researchers ex-
amined the following cell sublines resistant to particular drugs to analyze the differences in
CEBPD expression: cisplatin (NTUB1/P(14)), gemcitabine (NTUB1/G(1.5)), arsenic triox-
ide (NTUB1/As(0.5)), and paclitaxel (NTUB1/T(0.017)). CEBPD was only expressed in the
cisplatin resistant cell subline, NTUB1/P(14), and in none of the parental cell lines. When
treating NTUB1 cells with cisplatin, CEBPD protein and mRNA expression levels were uni-
laterally elevated across the cell lines. In determining its role in chemoresistance, CEBPD
was overexpressed in NTUB1 cells treated with increasing amounts of cisplatin. Compared to
controls, CEBPD overexpressed cells were significantly more resistant to cisplatin-induced
apoptosis. The paper further articulates that CEBPD reduces cisplatin-induced reactive
oxygen species (ROS) production by inducing the expression of Cu/Zn-superoxide dismu-
tase (SOD1) [161]. In a study of ototoxicity in mouse cells, CEBPD expression was also
affected by administration of cisplatin [158]. Another study in human found that cisplatin
upregulated CEBPD [162], which is consistent with Hour et al.
DOCETAXEL: (1/1)
Association: BATF with Docetaxel (see Direct Associations)
DOXORUBICIN: (3/3)
Association: HNF4G with Doxorubicin (see Direct Associations)
Association: HMGN3 with Doxorubicin
Observations: In the paper by Hanson et al., HMGN3 was silenced via siRNA in the negative
breast cancer cell line, MDA-MB-231. The knocked down cell lines were treated with either
doxorubicin or epirubicin. Compared to control, HMGN3 knockdowns were more resistant
to anthracycline-induced apoptosis in MDA-MB-231 cells, but not BTF459 [44]. In a study
profiling gene expression in 30 different cell lines treated with 11 different drugs, HMGN3
expression level was predictive of doxorubicin sensitivity across cells [163].
Association: TCF7L2 with Doxorubicin
Observations: TCF7L2 is a member of the WNT/-Catenin pathway. In a recent paper by
Vangipuram et al., the activity of this pathway was investigated in the context of chemore-
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sistance in cancer stem-like cells in a neuroblastoma cell line. To start, the investigators
segmented the SK-N-SH into resistant (CD133+) and sensitive groups (CD133-) to dox-
orubicin treatment. Pathway activity scoring showed suppression of the WNT pathway in
doxorubicin treated CD133- cells. WNT pathway genes were more differentially expressed
in CD133+ cells compared to CD133- cells. When treated with WNT agonists, doxorubicin
was very effective in reducing the population of CD133+ cells. This indicates that dox-
orubicin efficacy is related to the pathway activity of WNT/-Catenin [164]; however, this
doesnt necessarily link the drug directly to TCF7L2. A study in the mouse intestinal track
demonstrated that doxorubicin affects the expression TCF7L2 [165].
EPIRUBICIN: (3/4)
Association: HNF4G with Epirubicin (see Direct Associations)
Association: HMGN3 with Epirubicin (see HMGN3 with Doxorubicin)
Association: TAL1 with Epirubicin
Observation: TAL1 is expressed frequently in human T-cell acute lymphoblastic leukemia.
However, there are aberrations in the expression of TAL1 among leukemia cells. In inves-
tigating the cytotoxic effect of TAL1, Bernard et al. transfected human immature T-cell
lymphoid cell lines with TAL1. After treating with various cytotoxic agents including dox-
orubicin, the researchers concluded that the transfectants were more resistant to the cyto-
toxic effects of these drugs. TAL1 transfectants lacking a DNA binding domain did not show
altered sensitivity, revealing that TAL1 binding to DNA is important for this to occur. The
researchers, therefore, concluded that TAL1 acts at a late stage of the apoptotic cascade
[166]. While doxorubicin is not epirubicin, the two are very similar in structure, belonging
to the same drug class (anthracyclines). Additionally, the eQTL+M (TAL1, Doxorubicin)
association yielded an LLR score of 2.81, which barely missed our threshold of 3. Therefore,
we feel confident generalizing TAL1s association with doxorubicin to epirubicin.
GEMCITABINE: (3/5)
Association: ZNF143 with Gemcitabine
Observations: In looking at respiratory deficient mitochondrial cells, it was shown that cell
lines with respiratory dysfunction were more resistant to death via gemcitabine treatment
than their normal counterparts. It was also shown that such cells had higher ZNF143 mRNA
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levels compared to normal respiratory cells. While gemcitabine treatment with ZNF143
knockdown was not reported, dysfunctional cells showed greater sensitivity to cisplatin af-
ter ZNF143 was knocked down [167]. Thus, some evidence exists that ZNF143 can elicit
chemoresistance under certain circumstances.
Association: USF1 with Gemcitabine
Observation: Both gemcitabine and ara-C rely on deoxycytidine kinase (DCK) in the first
rate limiting steps of the activation of these nucleoside agents in solid tumors and leukemia,
respectively [168]. In vivo ChIP assays of HepG2 cells showed the presence of USF1/2 and
SP1/2 bound factors to the DCK promoter. Co-transfections in HepG2 showed activation
properties of USF1/2 binding and repressive properties of SP1 binding to a DCK-luciferase
reporter construct [169]. A separate study showed that DCK expression was predictive of
ara-C IC50 in acute myeloid leukemia (AML) cell lines; among the aforementioned regula-
tors of DCK, only USF1 expression was variable and correlated with DCK [168]. Given that
USF1 has been shown to regulate a gene important in the pharmacokinetics of both gemc-
itabine and cytarabine and is predictive of cytarabine IC50 in AML cell lines, we conclude
that there is some evidence to suggest USF1 is associated with gemcitabine.
Association: ZNF274 with Gemcitabine
Observation: A gene expression profiling of breast cancer cell lines in response to gemcitabine
treatment revealed numerous differentially expressed genes; ZNF274 was upregulated in re-
sponse to gemcitabine treatment [119].
HYPOXIA: (1/1)
HYPOXIA: (1/1)
Association: PRDM1 with Hypoxia
Observation: PRDM1 is one of two major transcription factors critical for XBP1 expression;
it does so by repressing PAX5, itself a repressor of XBP1, thereby enhancing XBP1 expres-
sion [170]. As it turns out, XBP1 is essential for hypoxia survival and is required for tumor
growth [171]. Though not TF siRNA evidence, we consider regulation of a gene essential for
treatment survival to be direct evidence of PRDM1s association with Hypoxia. In multiple
myeloma (MM) cells, researchers found that hypoxia induces the downregulation of plasma
specific TFs and upregulated stem-cell associated TFs. Among those TFs downregulated in
hypoxic MM cells compared to normoxic MM cells was PRMD1 [172]. Paradoxically, tran-
scriptomic profiling in other cells in hypoxic and normoxic conditions revealed upregulation
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of PRDM1 mRNA in response to oxygen deprivation [159] [173]. This suggests PRDM1 is
affected differently depending on the pathways induced by hypoxia.
NAPQI: (4/7)
Association: MEF2C with NAPQI (see Direct Associations)
Association: NFIC with NAPQI (see Direct Associations)
Association: CCNT2 with NAPQI (see Direct Associations)
Association: UBTF with NAPQI (see Direct Associations)
Association: BCLAF1 with NAPQI (see Direct Associations)
Observation: In a gene expression analysis of precision cut human liver slices, treatment of
APAP-induced upregulation of BCLAF1 [105]. BCLAF1 has also been shown to promote
cell death generally [174].
OXALIPLATIN: (5/7)
Association: STAT3 with Oxaliplatin (see Direct Associations)
Association: NANOG with Oxaliplatin (see Direct Associations)
Association: TRIM28 with Oxaliplatin
Observation: While there exists little direct evidence linking TRIM28 to oxaliplatin, studies
have shown that cisplatin increases phosphorylation [175] [176] and mRNA production (when
used in concert with piroxicam) [177] of TRIM28. One prominent study on three non-small
cell lung cancer (NSLC) cell lines transformed into tumor-initiating cells (TICs) via stem
cell media found impaired phosphorylation of TRIM28 due to irradiation and cisplatin treat-
ment; the researchers hypothesized that the inhibition of TRIM28 phosphorylation might
provide a mechanistic explanation for the observed reduction in DNA damage-induced cell
cycle arrest and apoptosis in NSCLC TICs [178]. This speaks more broadly to the phospho-
rylation of TRIM28 desensitizing DNA damaged cells to death rather than to its association
with a specific drug. Another very relevant study elucidating the connection between ataxia
telangiectasia and Rad3-related (ATR) protein inhibitors and cisplatin demonstrated in-
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creased phosphorylation due to mediation by ATR; the same cells sensitized by the ATR
inhibitor combined with cisplatin were also sensitized by the ATR inhibitor and oxaliplatin,
though to a lesser degree [179]. However, S-phase cell arrest via ATR appeared to be
sensitive to cisplatin, and not oxaliplatin [180], limiting the generalizability of the associ-
ation of discussion to oxaliplatin. Mechanistically, though, it is still plausible for there to
be an association. TRIM28 promotes re-sectioning of DNA double strand breaks not pro-
tected by -H2AX [181] in murine G1-phase lymphocytes and oxaliplatin has been shown
to induce -H2AX [182]. In terms of chemotherapeutic drugs more generally, a study found
that SKOV3 cells overexpressed with TRIM28 showed increased resistance to cisplatin and
paclitaxel [183], despite the notable differences in mechanism of action between platinum
agents and taxane therapies. Thus, while there is sufficient evidence between a TRIM28
and cisplatin association, there are mechanistic reasons to believe it can be generalized to
oxaliplatin, a drug of the same family as cisplatin. As for why TRIM28 was not reported as
an association with cisplatin, the best score (2.44) didnt make the cutoff threshold of 3 in
the eQTL+M analysis.
Association: FOSL1 with Oxaliplatin
Observation: An experiment involving the co-treatment of oxaliplatin with topotecan in
bone marrow from rats showed evidence of upregulation of FOSL1 when treated with this
cocktail [184]. In addition, FOS signaling has been shown to be activated by oxaliplatin
treatment in a variety of cancers [185]. In our analysis, FOS association with oxaliplatin
was also noteworthy with a score of 3.61, but it was not in the top 7 associated TFs with
oxaliplatin.
Association: ZEB1 with Oxaliplatin
Observation: In colon cancer cell line THC8307/L-OHP, oxaliplatin treatment downreg-
ulated ZEB1 expression [186]. ZEB1 has also been shown to increase tumorigenicity by
repressing stemness-inhibiting miRNAs like miR-203 [187], which has been shown to in-
crease oxaliplatin resistance in colorectal cancer cells [188].
Association: ATF1 with Oxaliplatin
Association: PPARGC1A with Oxaliplatin
Observation: PPARGC1A siRNA knockdowns were performed in colon cancer liver metas-
tases treated with the chemotherapeutic agents oxaliplatin and 5-fluorouracil (5-FU); knock-
down of PPARGC1A prevented chemotherapy-induced oxidative phosphorylation (OXPHOS).
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The study concluded that colorectal tumors shift energy production from glycolysis to OX-
PHOS via the SIRT1/PPARGC1A pathway [189].
PACLITAXEL: (2/3)
Association: GATA1 with Paclitaxel
Observation: Chronic myelogenous leukemia (CML) resulting from a t(9,22) translocation is
resistant to paclitaxel treatment. Researchers found that this produced an oncoprotein that
activated a GATA1 response element in the promoter of a heat shock protein, HSP70. The
siRNA knockdown of HSP7 0sensitized the cell to paclitaxel [190]. Additionally, a murine
study of the timeline of paclitaxel-induced cellular changes exhibited upregulation of GATA1
expression [191].
Association: E2F1 with Paclitaxel
Observation: Low dose application of paclitaxel human retinoblastoma cells exhibited up-
regulation of E2F1 [192]. Additionally, E2F1 overexpression in human osteosarcoma U2OS
cells sensitized the cells to paclitaxel [193].
RADIATION: (4/4)
Association: EZH2 with Radiation (see Direct Associations)
Association: ESR1 with Radiation
Observation: In a study examining the molecular mechanisms underlying the transforma-
tion of immortalized cells into tumorigenic cells, researchers found that ESR1, while low
expressed, was differentially expressed between immortalized mammary epithelial cells and
those induced into tumorigenesis via heavy-ion radiation [194]. A study examining the by-
stander effect, where cells respond to their neighbors, of irradiation in variable estrogen
receptor (ER) environments provides clearer proof of this association. The researchers irra-
diated MDA-MB-231 cells, which are ER negative, and MCF-7 cells, which are ER positive;
additionally, they treated both cells with 17-estradiol (E2), which activates ESR1, and ta-
moxifen, which is an E2 antagonist. MCF-7 cells, which have ESR1, exhibited increased
radiosensitivity and bystander response when treated with E2; the effect was diminished
by tamoxifen. E2 also increased MCF-7 reactive oxygen species (ROS), absent radiation;
however, in MDA-MB-231, neither the bystander response nor ROS increase was observed
[195]. Given that ESR1 activation sensitized MCF-7 cells to radiation, we consider this
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direct validation.
Association: PML with Radiation
Observation: Mouse embryo fibroblasts (MEFs) proficient and deficient in PML were irradi-
ated to determine the effect of PML in radiation-induced apoptosis. PML deficient cells were
much more resistant to radiation, indicating that PML mediates the apoptosis of radiation
therapy. Overexpression of PML upon cellular irradiation potentiated c-Jun transcriptional
activation and co-activation of c-Jun by PML was observed exclusively in irradiated cells.
ChIP experiments of irradiated and unaffected cells showed that binding of c-Jun to its
promoter was observed in irradiated, but not unaffected cells. Super shift analysis also
showed that the DNA binding ability of c-Jun/ATF-2 was comprised in PML deficient ir-
radiated cells [196]. A separate examination of the interaction between PML and TOPBP1
demonstrated that both co-localize in the nucleus of the cervical cell lines, SiHa, to repair
DNA damage after irradiation. Additionally, siRNA PML knockouts exhibited a decrease
in radiation-induced TOPBP1 expression, suggesting PML is a regulator of TOPBP1. How-
ever, overexpression of PML did not increase mRNA levels of TOPBP1, but did increase
TOPBP1 protein expression. Furthermore, pulse-chase labeling experiments indicated that
PML increases the half-life of TOPBP1 protein, indicating that this regulation occurs at the
post-transcriptional level [197]. A separate analysis in HeLa cells treated by radiation and
cisplatin showed upregulation of PML protein in response to treatment, although northern
blotting did not indicate a gross increase in mRNA levels. Transfection of p53 into HeLa
upregulation of PML with respect to control, indicating that PML is regulated by the p53
pathway [198].
Association: HDAC2 with Radiation
Observation: In non-small cell lung cancer (nsCL) BE1 cells, HDAC1 and HDAC2 expression
were highly correlated and significantly higher than normal tissues. Prognosis of patients
with low expression of these HDACs was noticeably higher compared to high expression
patients. Irradiation of BE1 cells downregulated HDAC1 and HDAC2 expression and up-
regulated AXIN expression. Knockdowns of HDAC1 and HDAC2 via siRNA upregulated
AXIN expression as well. Radiation treatment combined with HDAC knockdown in BE1
cells expressing AXIN increased apoptosis of cells compared to radiation treatment alone
[199]. In fact, there is a growing body of literature that suggest combination therapies of
HDAC inhibitors with radiation in chemotherapy treatment [200].
RAPAMYCIN: (3/3)
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Association: GATA1 with Rapamycin (see Direct Associations)
Association: STAT2 with Rapamycin
Observation: An experiment treating lung adenocarcinoma cells (A549) with rapamycin
identified STAT1 interacting with mTOR and increased STAT1 nucelar concentration after
rapamycin treatment [201]. While STAT1 is not STAT2, the two form heterodimers and are
members of the same protein family. Additionally, the pGENMI STAT1 association with
Rapamycin score was 2.49, which though below threshold, is very similar to the STAT2
score. We believe that STAT2 is interpreting the same signal in this context and thus the
association is valid. This association was also validated in our own experimental validations
of the effect of STAT2 knockdown on rapamycin treated MDA-MB-231 cells.
Association: PHF8 with Rapamycin
Observation: A study showed that PHF8 mRNA and protein levels were downregulated in
failing human and mice hearts undergoing hypertrophy. Overexpression of PHF8 identi-
fied the aKT/mTOR pathway as a target of PHF8. When this pathway was inhibited by
treatment of rapamycin, the phenotype lost by PHF8 deficiency was rescued [202]. As in the
previous two associations with rapamycin, we corroborated this association in the laboratory.
TRICIRIBINE: (2/2)
Association: REST with Triciribine
Observation: A study of the regulatory dynamics of REST in small cell lung cancer revealed
a putative binding site for REST at the 3 end of the AKT2 UTR. Previous studies had
shown that siRNA mediated knockdown of REST correlated with increased AKT phospho-
rylation. In this particular study, siRNA knockdown of REST resulted in upregulation of
AKT2. Temporal gene expression profiling also showed high AKT2 expression in small cell
lung cancer cell lines only days after high expression of REST diminished [203]. Though
we lack direct evidence, given RESTs regulation of AKT2 and triciribines role as an AKT-
inhibitor, we are confident in confirming this association at least partially.
Association: NANOG with Triciribine
Observation: While we lack direct evidence of NANOGs association with triciribine, there is
plenty of data linking NANOG with AKT. For instance, a study showed that the PI3K/AKT
pathways is important in mediating the regulation of NANOG during differentiation of em-
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bryonic carcinoma F9 cells [204]. Another study elucidated that AKT-mediated phospho-
rylation is crucial for repression of NANOG in differentiating murine embryonal carcinoma
cells [205]. Taken together, we believe there exists a plausible connection between NANOG
and the AKT inhibitor triciribine.
TEMOZOLOMIDE: (3/7)
Association: FOXM1 with Temozolomide (see Direct Associations)
Association: RELA with Temozolomide (see Direct Associations)
Association: EBF1 with Temozolomide
Observation: In the treatment of glioblastoma, temozolomide works by operating as a methyl
donor for the alkylation of the N-7, O-3, and O-6 positions of nucleotide bases, initiating a
DNA repair process that cannot undo this level of damage. O-6-methylguanine methyltrans-
ferase (MGMT) removes methyl groups from the O-6 position of guanines, thereby rendering
temozolomide ineffective [206]. IDH1 mutations have been shown to predict longer survival
times via treatment of temozolomide [207]. It has also been shown that EBF1 can bind to
both DNA and TET2 and function as a demethylation agent in IDH1 mutants [208]. Thus,
EBF1 may have a role to play in differential methylation of the MGMT promoter in IDH1
mutants, and thus have a role to play in cellular response to temozolomide.
Association: ELF1 with Temozolomide
Observation: While we did not find any literature evidence for this association, we validated
it through TF siRNA in U251 glioma cells.
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APPENDIX B: PGENMI: FULL CYTOTOXICITY GRAPHS
This appendix contains all 25 pGENMi cytotoxicity graphs, grouped by drug and cell
line. Red captioned graphs refer to validated experiments. All experiments were motivated
by either a negative control or positive eQTL+M model. For brevity, all experiments are
presumed to be positively motivated, unless stated otherwise.
Figure B.1: (6-MP, Jurkat): Cytotoxicity experiments for 5 TFs, in which FOXP2 and
EZH2 were negative controls, and EZH2 was validated.
(a) EZH2 (b) FOXP2
(c) WRNIP1 (d) RCOR1
(e) PAX5
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Figure B.2: (6-TG, Jurkat): Cytotoxicity experiments for 5 TFs, in which FOXP2 and
EZH2 were negative controls and neither validated.
(a) EZH2 (b) FOXP2
Figure B.3: (Ara-C, Jurkat): Cytotoxicity experiments for UBTF and RAD21 - which
validated.
(a) RAD21 (b) UBTF
Figure B.4: (Taxanes, MDA-MB-231): Cytotoxicity experiments for a negative control,
CHD1, and BATF, which validated.
(a) (CHD1, Paclitaxel) (b) (BATF, Docetaxel)
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Figure B.5: (Rapamycin, MDA-MB-231): Cytotoxicity experiments for GATA1,
STAT2, and PHF8, which all validated.
(a) GATA1 (b) Rapamycin
(c) PHF8
Figure B.6: (Various, MDA-MB-231): Cytotoxicity experiments for (TCF7L2, Epiru-
bicin), (USF1, Gemcitabine), and (PML, Radiation).
(a) (TCF7L2, Epirubicin) (b) (USF1, Gemcitabine)
(c) PML
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Figure B.7: (Platinum Agents, MDA-MB-231): Cytotoxicity experiments for 3 negative
controls, (TBL1XR1, Carboplatin), (EZH2, Cisplatin), (NR3C1, Oxaliplatin), and (CEBPD,
Cisplatin), which validated.
(a) (CEBPD, Cisplatin) (b) (EZH2, Cisplatin)
(c) (TBL1XR1,Carboplatin) (d) (NR3C1,Oxaliplatin)
Figure B.8: (Temozolomide, U251): Cytotoxicity experiments for FOXM1, SMARCC2,
ZNF263, and ELF1, which validated.
(a) FOXM1 (b) ELF1
(c) SMARCC2 (d) ZNF263
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